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ABBREVIATIONS
AN = anorexia nervosa
APA = American Psychiatric Association
ASP = antisocial personality disorder
ASPs = persons with antisocial personality disorder
AST = actual sleep time
BMI = body mass index
BNSQ = Basic Nordic Sleep Questionnaire
BPD = borderline personality disorder
CD = conduct disorder
CDT = carbohydrate deficient transferrin
EEG = electroencephalogram
EMG = electromyogram
EOG = electro-oculogram
GH = growth hormone
GT = gamma-glutamyl transferase
5-HT = 5-hydroxytryptamine = serotonin
IGF = insulin-like growth factor
IED = intermittent explosive disorder
IQ = intelligence quotient
PFC = prefrontal cortex
PSG = polysomnography
REM = rapid eye movement sleep
S1-S4 = sleep stages 1-4
SCID = Structured Clinical Interview for Disorder
SE = sleep efficiency
SEM = standard error of the mean
SPA = spectral power analysis
SWS = slow wave sleep
TST = total sleep time
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SUMMARY
Disturbed sleep is a common complaint in psychiatric patients. Sleep problems can
be either the cause or the consequence of psychiatric distress, and they may also
appear together as a core symptom of a particular psychiatric diagnosis. In health
care, it is often common practice to describe sleep medication for a psychiatric pa-
tient. In fact, the practice is often so automatic that a deeper understanding of the
specific nature of the problem remains to be lost. However, it has been suggested that
the appropriate intervention for sleep problems may either relieve the symptoms of
the psychiatric disorder or in some cases even prevent them. The quality of sleep is
constituted of many components, but one of the most important factors is its normal
structure. This emphasizes the importance of studying the effects of psychiatric
medication on sleep architecture. PSG, which is a time-consuming procedure requir-
ing special expertise, can hardly be used as a standard method for all psychiatric
patients with sleep problems. In some cases, however, it is has been shown to be
useful and should be available in psychiatric hospitals for clinical use and not just as
an academic research method. The less burdensome methods like actometry and
static charge sensitive bed (SCSB) (Alihanka et al., 1981) should not be forgotten in
clinical work.
Since the discovery of REM sleep in the 1950s, psychiatric sleep research has focused
on the role of REM sleep by studying both the dreaming and the association between
REM parameters and psychiatric disorders. However, the focus has recently shifted
to SWS, which has been shown to be a sensitive indicator of both somatic and psychi-
atric disturbances. In this work, in spite of the difference in the chosen psychiatric
disorders (AN and ASP), the changes in sleep parameters compared with healthy
controls were seen in non-REM sleep, and particularly in SWS. The changes in REM
sleep appear to be typically associated with major depression, the disorder, which was
excluded from this work.
The abnormal sleep architecture may serve as a marker of specific pathology, as seen
previously in narcolepsy. The high amount of S4 sleep in habitually violent offenders
with ASP is an unusual phenomenon. This finding, although still preliminary, may
prove to be a specific marker of brain pathology associated with extreme impulsive
aggression.
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1. INTRODUCTION
1.1. Normal human sleep
1.1.1.  General
Human sleep consists of two main components, rapid eye movement sleep (REM)
and non-REM sleep, the latter divided into stages 1–4 (S1–S4). S3 and S4 in non-
REM sleep are defined as slow wave sleep (SWS), also called delta sleep or deep
sleep. The four non-REM stages roughly parallel a depth of sleep continuum, with
arousal thresholds generally at their lowest in S1 and at their highest in S4. A healthy
adult enters sleep through non-REM sleep and REM does not occur until 80 minutes
or more thereafter. In normal sleep, REM and non-REM sleep periods alternate cy-
clically throughout the night so, that deep sleep predominates in the first third of the
night, while REM sleep predominates during the last third of the night (Borbély,
1986a). The duration of nocturnal sleep is dependent on a number of factors. Most
young adults report sleeping approximately 7.5 hours a night on weekday nights and
slightly longer, 8.5 h, on weekend nights. The variability of these figures from per-
son to person and from night to night is, however, quite high (Carskadon and
Dement, 2000). Although the exact functions of the different sleep stages are not
known, it is generally accepted that SWS is the physiologically significant, refresh-
ing part of sleep (Carskadon and Dement, 2000). REM sleep is associated with
dreaming, based on vivid dream recall reported after approximately 80 % of arousals
from this state of sleep (Dement and Kleitman, 1957).
1.1.2. Assessment of sleep
1.1.2.1. Sleep questionnaire
One of the best methods for obtaining an overview of the patient’s subjective sleep
quality is a retrospective sleep questionnaire (Spielman et al., 2000). Questionnaires
have the advantage of being able quickly to summarize the sleep events that have
occurred over a long period of time.
1.1.2.2.  Sleep diary
Unlike sleep questionnaires, a sleep diary offers a prospective method for studying
the patient’s sleep behavior. Filling in a sleep diary directs the patient’s attention to
aspects of behaviour that might otherwise be overlooked and in some versions
presents the information in a graphic format that allows the clinician quickly to
survey large amounts of data (Spielman et al., 2000). Filling in a diary before the
treatment also provides a baseline against which the treatment response can be meas-
ured.
1.1.2.3.  Actometry
Actometry and actigraphy are used in the literature as synonyms for recording meth-
ods based on accelerometric sensors. They react to acceleration signals produced by
body movements. The data that are collected are displayed on a computer and are
10
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examined for activity versus inactivity and analysed for wakefulness versus sleep.
Wrist actometry technology is based on the fact that during sleep, there is little move-
ment, whereas, during wakefulness, there is increased movement. Wrist actometry
has the advantage of being cost efficient, allowing the recording of sleep in natural
environments, recording behaviour that occurs during both the night and the day, and
recording for long time periods (Ancoli-Israel, 2000).
1.1.2.4.  Polysomnography
The golden standard for the evaluation of the patient’s sleep structure is
polysomnography (PSG), which includes the electrophysiological recording of brain
cortex activity by electroencephalography (EEG), eye movements by electro-
oculography (EOG), and skeletal muscle tone by electromyography (EMG). The
recordings can be visually scored as either wakefulness or different stages of sleep
(S1-S4, REM) in epochs of 30 seconds (Rechtschaffen and Kales, 1968) in order to
draw a patient’s sleep histogram. A PSG provides a great deal of  information about
the chosen study night.
1.1.2.5.  Spectral power analysis
The EEG spectral power analysis (SPA) is used to provide more accurate informa-
tion about sleep than traditional PSG; while the sleep scoring is based on a subjective
evaluation of the recording, SPA is fully computerized. It quantitates the amplitude
of different frequency bands (beta, sigma, alpha, theta and delta) of the EEG record-
ing.
1.1.3. Sleep regulation
1.1.3.1. The two-process model
According to a current and widely accepted model of non-REM sleep regulation,
sleeping is controlled by two separate components: circadian process C, which affects
the appropriate timing of sleep and homeostatic process S, which accounts for a
sufficient amount of sleep (Borbély, 1982). The circadian process C is mainly con-
trolled by the rhythmic activity of the suprachiasmatic nucleus in the hypothalamus.
In the case of the homeostatic process S, no single locus has been found in the central
nervous system. It appears instead to be controlled by several neural systems, which
are localized in the hypothalamus, basal forebrain, and brain stem nuclei (Borbély
and Tobler, 1989).
1.1.3.2. Neurotransmitters regulating sleep
The biochemical regulation of sleep can be divided into three functionally different
domains. The wake promoting system includes the classic aminergic neurotrans-
mitters serotonin, noradrenaline and histamine as well as acetylcholine. The pontine
monoaminergic nuclei and hypothalamic histaminergic neurons have the highest fir-
ing rate in waking, decreased in SWS and the lowest in REM sleep. The cholinergic
neurons are an exception, as they have the same level of activity during both in
waking and in REM sleep. Firing of midbrain dopaminergic neurons of the substan-
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tia nigra and ventral tegmental area does not seem to vary in phase with the REM-
NREM cycle, and it is supposed that the effects of dopamine on normal sleep might
be mediated by its interactions with other neurotransmitter systems (Pace-Schott and
Hobson, 2002). The sleep promoting system includes both the major inhibitory neu-
rotransmitter gamma-aminobuturic acid (GABA), and adenosine, which has proved
to be an important homeostatic factor. In cats, the accumulation of adenosine during
wakefulness has been shown to induce sleep (Porkka-Heiskanen et al., 1997). The
modulatory factors include a variety of molecules often of polypeptide structure,
such as growth hormone (GH) (Jones, 2000).
1.1.4. The physiological significance of different frequency bins in the power
spectrum
The spectral power in the delta range (0.5–3.5 Hz) correlates with the intensity
(“depth”) of stage 3+4 sleep, and can be used as an objective measure of the intensity
of SWS (Borbély, 1986b). Low delta power is generally regarded as a sign of poor
sleep quality, and delta power is reduced in many conditions, including mental disor-
ders (Keshavan et al, 1995). Less is known about the correlates of the theta range
(3.5–8.5 Hz), although reductions in theta power have been described in patients
with schizophrenia, for example (Keshavan et al., 1998). Both delta and theta power
decline across the night and increase with the duration of wakefulness preceding
sleep as markers of the homeostatic sleep process (Borbély et al., 1981). The physi-
ological roles of the higher frequency powers remain somewhat speculative at
present. The delta, theta and sigma (12.0–14.5 Hz) powers have been reported to
decrease and the beta (14.5–25 Hz) power to increase during aging by Carrier et al.
(2001).
1.2. Sleep disturbances in the light of epidemiological studies
1.2.1.  The prevalence of sleep disturbances
Disturbed sleep is a common complaint and source of distress in community surveys
of self-reported health problems (Ohayon, 2002). Hublin et al. (1996) reported  that,
in the general Finnish adult population, 11.0% of women and 6.7 % of men suffered
from daytime sleepiness every or almost every day. Insomnia at least every other day
was reported by 20.7 % of women and 28.6 % of men. Among those with daytime
sleepiness, 11 % used hypnotics or tranquillizers on more than 180 days per year.  In
the Swedish population, complaints of sleeping difficulties (i.e. pronounced diffi-
culty in falling asleep, nocturnal awakenings, and/or premature morning awak-
enings) were reported by 15.3% of all subjects (Lindberg et al., 1997). Difficulty
maintaining sleep, the absence of feeling refreshed in the morning, and excessive
daytime sleepiness were more common among females than males. In an epidemio-
logical study by Quera-Silva et al. (1991) in France, 10% of the population reported
the use of hypnotics, with 6.2 % indicating frequent and chronic use for more than
six months. The group who most frequently used hypnotics were women aged 45
years and older.
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1.2.2.  The co-morbidity of sleep problems and mental disorders
Bixler et al. (1979) conducted the first study, which included a section on mental
disorders in interviews with persons with insomnia (difficulty in initiating or main-
taining sleep). They found that 19.4 % of insomniacs had depression, 50% had emo-
tional problems, and 35.7% had a recurring health problem. However, the study was
based on the individual’s own perception.  In a survey of insomniacs investigated in
general practice, Hohagen et al. (1993) using DSM III R criteria, found a high level
of comorbidity for severe insomnia with psychiatric disorders. Of 150 severe insom-
niacs, 21.7% were diagnosed as having depression, 7.2% neurosis/personality disor-
ders, 4.6% alcohol or drug abuse, 5.6% psychosomatic disorders, 1% psychosis, and
1.3% organic brain syndrome. When it came to the different diagnostic subgroups,
severe insomnia was consistently shown to have a highly significant association with
all psychiatric diagnoses, while moderate insomnia was only associated with the di-
agnosis of depression. In a study by Schramm et al. (1995), 50% of patients with
current insomnia in general practice also had at least one additional current axis I or
II diagnosis. Affective disorders were the most common principal psychiatric diag-
nosis, followed by substance abuse disorders. The predominant personality was char-
acterized by avoidant, dependent, obsessive-compulsive and passive-aggressive fea-
tures. In a study by Ford and Kamerow (1989), almost 8000 individuals were ques-
tioned about sleep complaints and psychiatric symptoms at baseline and one year
later. The diagnoses were made using DSM III criteria. Of this community sample,
10.2% reported insomnia and 3.2% hypersomnia (excessive sleepiness) at the first
interview. Forty per cent of those with insomnia and 46.5% of those with hypersom-
nia had a psychiatric disorder, compared with 16.4 % of those with no sleep com-
plaints. The most common disorders in patients with sleep complaints were anxiety
disorders including phobias, obsessive-compulsive disorder, and panic disorder. De-
pressive disorders and alcohol and drug abuse disorders were also common. The most
important finding was that individuals with continuing insomnia had significantly
higher rates of new cases of both major depression and anxiety disorders compared
with those whose insomnia had been resolved.  Individuals with continuing hyper-
somnia also had higher rates of new cases of major depression and anxiety disorders,
although the numbers were smaller than those for individuals with insomnia. In a
longitudinal epidemiological study of young adults by Breslau et al. (1996), lifetime
associations with specific psychiatric disorders were as high for insomnia and hyper-
somnia, and persons with a history of both disturbances had higher rates of psychiat-
ric disorders than those with either of the disturbances alone. The strongest lifetime
association of sleep disturbance was major depression, even when a diagnosis of
major depression was made on the basis of symptoms other than sleep disturbance.
A history of either type of sleep disturbance at baseline signalled an increased risk of
a new onset of major depression, illicit drug use disorder, and nicotine dependence.
Breslau et al. pointed out that complaints of two weeks or more of insomnia almost
every night could be regarded as a useful marker of the subsequent onset of major
depression. Weissman et al. (1997) reported data from an epidemiological commu-
nity survey of more than 10,000 adults. The major findings were that insomnia, even
when uncomplicated by a psychiatric disorder, is associated with increased treatment
seeking from the general medical or psychiatric speciality sectors, and with an in-
creased risk of subsequent first onset of major depression, panic disorder, and alcohol
13
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abuse one year later. The findings suggest that early intervention for insomnia may
be an opportunity for preventing subsequent psychiatric disorders.
So, as Balter et al. (1992) concluded, “Sleep problems can be either the cause or the
consequence of psychiatric distress. They can also appear together as a core symptom
of a particular psychiatric diagnosis such as depression, post traumatic stress disorder
and addiction”. The relationship between sleep abnormalities and psychiatric disor-
ders is not, however, clearly understood, in spite of many investigations, and more
research has to be conducted in order to answer this difficult question more reliably
(Léger, 2000).
1.3. The polysomnography in psychiatric disorders
Many investigations of sleep in psychiatric disorders over the past few decades have
attempted to identify diagnostically sensitive and specific sleep patterns associated
with particular disorders. Psychiatric sleep research has focused most intensively on
REM latency reduction in affective disorders, as it appears to be most specific in
distinguishing depressive patients from both normal subjects and those with other
psychiatric disorders (Benca et al., 1992). Benca et al. reviewed a total of 177 studies
using visual scoring methods with data for 7151 patients with different psychiatric
disorders and controls in order to clarify the possible association between specific
sleep patterns and psychiatric disorders. Most psychiatric groups displayed a signifi-
cant reduction in sleep efficiency (SE) and total sleep time (TST), accounted for by
decrements in non-REM sleep. REM sleep was relatively preserved in all groups,
while REM % was increased in affective disorders. A reduction in REM latency was
observed in affective disorders but occurred in other categories as well. Although no
single sleep variable appeared to have absolute specificity for any particular psychiat-
ric disorder, patterns of sleep disturbances associated with categories of psychiatric
illnesses were observed. As the authors commented, further studies are needed to
determine the diagnostic sensitivity and specificity of sleep disturbances in a variety
of primary and secondary psychiatric disorders, their clinical usefulness, and the
pathophysiological mechanisms of sleep disturbances in clinical disorders.
1.4.  Sleep and schizophrenia
It is a well-known fact that one of the major symptoms of schizophrenia is sleep
disturbance (Benson and Zarcone, 2000). The sleep of  patients with schizophrenia is
characterized by poor SE, which often takes the form of long sleep onset latencies
and reduced total sleep. Sleep continuity is also impaired by long periods of waking
after sleep onset (Ganguli et al., 1987; Tandon et al., 1992; Lauer et al., 1997).
Reduced REM sleep latency, also reported in schizophrenia, has been attributed to
cholinergic hyperactivity secondary to increased dopaminergic tone (Tandon et al.,
1992). The secretion of prolactin is inhibited by dopamine. In a study by Appelberg
et al. (2002) a positive correlation between serum prolactin levels and REM latency
was found in patients with non-affective psychosis. It has been suggested that the
reduction in SWS is the prevailing alteration in the sleep of patients with schizophre-
nia (Keshavan et al., 1995). The reduction in SWS tends to persist after the clinical
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remission of psychotic symptoms (Maixner et al., 1998). Some correlation between
the reduction in SWS and ventricle size in  patients with schizophrenia has been
reported (van Kammen et al., 1988; Lauer and Krieg, 1998). SPA reveals reductions
in delta and theta power in  patients with schizophrenia (Keshavan et al., 1998).
The fact that schizophrenia, as well as other psychotic disorders, is associated with
serious sleep disturbances underlines the importance of finding antipsychotics, which
are efficacious in inducing sleep, especially delta and theta sleep.
1.4.1. Olanzapine
Olanzapine is a novel antipsychotic medicine with proven efficacy in schizophrenia
(Beasley et al., 1997). It has shown a high affinity for serotonin 5-HT2A, 5-HT2C,
5-HT3, 5-HT6, histamine H1, dopamine D1, D2, D3, D4, alpha1-adrenergic and
muscarinic receptor subtypes in vitro (Bymaster et al, 1999, 2001). In healthy volun-
teers and in patients with schizophrenia, olanzapine occupied more 5-HT2 receptors
than D2-receptors in positron emission tomography (Nyberg et al., 1997; Kapur et
al., 1999). In single- photon emission tomography (SPET) scan studies with a spe-
cific 5-HT2A ligand, increased binding in the frontal cortex compared with the cer-
ebellum was seen in healthy subjects (Busatto et al., 1997). The pharmacological
profile of olanzapine, with a prominent affinity for 5-HT2 and H1 receptors sug-
gested that it may have hypnogenic effects on both patients with schizophrenia and
healthy subjects.
1.4.2. Polysomnographic studies of olanzapine
Sálin-Pascual et al. (1999) described polysomnographic findings in 20 drug-free (at
least two weeks before entering the study)  patients with schizophrenia after the acute
administration of 10 mg of olanzapine. They found significant increases in the total
sleep time, REM density, S2 sleep and SWS. Sharpley et al. (2000) reported the
effects of olanzapine on sleep in nine healthy males. Compared with placebo, both
the 5-mg and 10-mg doses of olanzapine significantly increased SWS, sleep continu-
ity measures, and subjective sleep quality. In addition, 10 mg of olanzapine sup-
pressed REM sleep and increased REM sleep latency. The metabolism of drugs has
been found to differ between the sexes (Poolsup et al., 2000), suggesting that medi-
cation may affect sleep differently among females and males. In the study by Sálin-
Pascual et al. (1999), the patient group consisted of both females and males, but the
results were not analysed separately. There are no published sleep EEG studies in
which the effects of olanzapine on females are described.
1.5. Sleep in anorexia nervosa
Eating disorders are most prevalent during adolescence and young adulthood, respec-
tively, an age range in which sleep tends to be least disturbed by psychiatric illness
(Benca and Casper, 2000). Nevertheless, sleep disturbances are common in patients
with AN and abnormalities in sleep architecture have been documented. Anorectics
have been described as having shorter total sleep time, reduced SE, and more S1
sleep than controls (Crisp et al., 1971;Walsh et al., 1985; Levy et al., 1988). They
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have also been reported as having less SWS (Neil et al., 1980; Levy et al., 1988), and
a positive correlation between BMI and the amount of slow-wave activity in the delta
range (0.5–4.5 Hz) has been reported (Nobili et al., 1999). Neil et al. (1980) and
Katz et al. (1984) demonstrated  shorter REM latency in AN compared with controls,
while in many studies this phenomenon has not been observed (Walsh et al., 1985;
Levy et al., 1988; Lauer and Krieg, 1992). The weight gain has increased total sleep
duration as well as SWS (Crisp et al., 1971; Lacey et al., 1975; Lauer and Krieg,
1992).
1.5.1.  The GH-IGF-1 axis and leptin in anorexia nervosa
Growth hormone (GH), a major anabolic hormone of the body, is secreted by the
anterior pituitary gland.  The synthesis and release of GH is controlled by the
hypothalamus via two neurohormones, growth hormone releasing hormone (GHRH)
and somatostatin. GHRH stimulates GH production and release and somatostatin in-
hibits them. The secretion of GH is pulsatile. The secretion bursts are flanked by
almost undetectable levels of plasma GH. In humans, there is typically one high
secretion pulse and a few lower ones during the 24-h day-night span (Van Cauter et
al., 1998). Several studies report an increase in GH secretion, both basal and
pulsatile, in anorectic patients (Scacchi et al., 1997; Stoving et al., 1999). In a study
by Argente et al. (1997), two distinct groups of anorectics were found; those who
hypersecreted GH (38%) and those whose GH secretion was reduced (62%). After
recovering 10% or more of their initial weight, the GH secretion in both groups had
normalized.
The effects of GH are partly mediated by somatomedins of which the most important
ones are insulin-like growth factors (IGF) 1 and 2. Although somatomedins are se-
creted locally by several tissues, the plasma IGF-1 content mostly originates from the
liver and kidneys. IGF-1 stimulates aminoacid transport, protein synthesis and body
growth (Thissen et al., 1994). In patients with eating disorders, IGF-1 appears to be
a biochemical marker of malnutrition, and a sensitive index of nutritional repletion
(Caregaro et al., 2001). A stepwise increase in the IGF-1 values related to weight
gain in anorectic patients was reported by Hill et al. (1993).
Leptin is syntetized in adipose tissue, but it regulates food intake via the
hypothalamus. Leptin levels correlate with the amount of fat stores and changes in
energy balance as a result of fasting (Ahima et al., 2000). Leptin levels are severely
reduced in AN patients, but a significant rise already occurs after partial weight
recovery (Grinspoon et al., 1996; Casanueva et al., 1997).
1.5.2.  The GH-IGF-1 axis, leptin and sleep
GHRH promotes non-REM sleep in both animals and humans (Obal et al., 1988;
Steiger et al., 1992). GHRH enhances both non-REM sleep duration and its intensity,
as measured by slow-wave activity on the sleep EEG. The inhibition of GHRH
through negative feedbacks in the somatotropic axis inhibits non-REM sleep (Obal et
al., 2001). In human studies, systemic injections of somatostatin failed to alter sleep
in young subjects but impaired sleep in the elderly (Frieboes et al., 1997). The main
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secretion pulse of GH is closely associated with the beginning of the sleep phase
when the amount of SWS is at its highest (Van Cauter et al., 1992). The delay,
advance or interruption of a sleep phase will shift the main GH secretion pulse corre-
spondingly (Goldstein et al., 1983; Van Cauter et al., 1992). Sleep deprivation also
inhibits nocturnal GH secretion, while the pulses become more equally distributed
through the day (Brandenberger et al., 2000). In animals, antibodies to GH have been
shown to reduce non-REM sleep (Obal et al., 1997). It has been hypothesized that
chronically high or low GH secretions, may alter non-REM sleep in humans
(Åström, 1997).
The injection of a high dose of IGF-1 promptly inhibited sleep in rats (Obal et al.,
1999). The inhibition of sleep occurs simultaneously with the inhibition of GH secre-
tion and  is attributed to the inhibition of GHRH. Low doses of IGF-1, however,
increase non-REM sleep (Obal et al., 1998). In humans, the serum concentration of
IGF-1 has been found to have a positive correlation with non-REM sleep quality
measured as delta power (Prinz et al., 1995).
Leptin secretion has a circadian variation, with maximum levels in humans during
the night, and a nadir late in the afternoon (Simon et al., 1998). In normally- fed rats,
leptin administration increased the duration of SWS, but previous food deprivation
negated this effect (Sinton et al., 1999).
To summarise, it can be concluded, that AN is a disorder associated with both severe
hormonal disturbances, and changes in sleep architecture. Several of the hormones
displaying disturbed secretion in anorectic patients have also been shown to have
effects on sleep, but the correlation between the disturbed sleep and hormone secre-
tion has not been measured in anorectic patients.
1.6.  Sleep and human impulsive aggression
1.6.1.  Different dimensions of impulsive aggression
As a symptom impulsive aggression cuts across a number of psychiatric disorders
(Moeller, 2001), but it is commonly associated with personality disorders, in particu-
lar antisocial (ASP) and borderline (BPD) personality disorders (Eronen et al., 1996;
Virkkunen et al., 1996, Goodman and New, 2000, Skodol et al., 2002). In fact,
genetic, neurobiological, and diagnostic studies suggest a dimensional approach to
BPD symptomatology, with impulsive aggression as one of the core dimensions of
the disorder (Goodman and New, 2000; Siever et al., 2002). ASP is associated with a
pervasive pattern of disregard for and the violation of the rights of others. Not sur-
prisingly, the highest prevalence rates of ASP are found in prisons and forensic set-
tings (American Psychiatric Association (APA), 2000). In a study by Fazel and
Danesh (2002), 47% of male prisoners had ASP. ASP often co-occurs with BPD
(Coid, 1993; Virkkunen et al., 1994; Hudziak, 1996; Virkkunen et al., 1996) and it
has even been suggested that BPD represents a female form of male-predominant
ASP (Gunderson and Zanarini, 1987). The comorbidity of BPD with ASP increases
the likelihood of suicide attempts (Soloff et al., 1994).
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ASP is always preceded by conduct disorder (CD) before the age of 15 (APA, 2000).
The essential feature of CD is a repetitive and persistent pattern of behaviour in
which the basic rights of others or major age-appropriate societal norms or rules are
violated (APA, 2000). Impulsivity has been found to be the best predictor of conduct
problems (Vitacco and Rogers, 2001) and impulsivity together with emotional
lability may increase the likelihood of CD progressing to adult antisocial behaviour
(McKay and Halperin, 2001). A strong relationship between adolescent suicide and
the presence of CD problems, especially in coexistence with depression and alcohol
abuse, has been reported in a study based on a Finnish nationwide population
(Marttunen et al., 1991).
Attention deficit hyperactivity disorder (ADHD) is the most common psychiatric
disorder of childhood (Szatmari, 1992).  The combined type of ADHD fulfills both
the criteria for attention deficit as well as for hyperactivity and impulsiveness,
whereas the subtypes (predominantly inattentive and predominantly hyperactive and
impulsive type) do not fulfill the criteria for both symptom dimensions (APA, 1994).
Prospective longitudinal studies have showed that part of the childhood onset ADHD
symptoms persists in nearly half of the subjects until adolescence or early adulthood
and that ADHD is a risk factor for conduct disorder, ASP and substance abuse
(Gittelman et al., 1985; Mannuzza et al., 1993).
It has been argued that many individuals with personality disorders display a clini-
cally significant impulsive-aggressive behaviour, which cannot be specifically identi-
fied by using axis II personality disorder diagnoses (Coccaro et al., 1998). In these
cases, it would be better to use the diagnosis of intermittent explosive disorder (IED),
which may best be regarded as a categorical expression of recurrent, problematic
impulsive and aggressive behaviour (Coccaro, 2000). The essential core features of
IED are: 1) the occurrence of discrete episodes of failure to resist aggressive impulses
that result in serious assaultative acts or the destruction of property and 2) the degree
of aggressiveness expressed during an episode is grossly out of proportion to any
provocation. Besides in the research purposes, the diagnosis can also be placed to
individuals with ASP and BPD in cases where impulsive aggression has specific
clinical relevance (APA, 2000).
1.6.2.  Testosterone and aggression
The relationship between testosterone and human aggression has been well estab-
lished in many studies. High concentrations of serum testosterone have been shown
to be associated with both ASP (Virkkunen et al., 1994) and severe CD (Brooks and
Reddon, 1996). In a study by Stalenheim et al. (1998) serum levels of total testoster-
one were related to both ASP and type II alcoholism. In the study by Räsänen et al.
(1999), personality-disordered criminals with multiple offences had higher serum
testosterone levels than criminals with schizophrenia or healthy controls. Antisocial
behaviour has been shown to be present in both rapists and child molesters and to be
positively related to salivary testosterone concentrations (Aromäki et al., 2002).
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1.6.3.  Sleep in borderline personality disorder
BPD co-occurs with several axis I and axis II diagnoses (Cloninger and Svrakic,
2000). The problem in most of the PSG studies in BPD is that this existence of a
concomitant disorder is not taken into account (De la Fuente et al., 2001). Only four
studies have clearly considered the existence of additional psychiatric diagnoses in
their BPD patients. Akiskal et al. (1985) found reduced REM latency in both  pa-
tients with major depression but no BPD comorbidity and patients with BPD but no
major depression comorbidity compared with healthy controls. Reduced REM la-
tency compared with controls has also been reported in a study by Battaglia et
al.(1993). In a study by Benson et al. (1990), non-affective BPD patients had less
total sleep, more S1 sleep and less S4 sleep compared with normal controls. In the
study by De La Fuente et al. (2001), BPD patients had shorter total sleep time, longer
sleep onset latency and a greater percentage of wakefulness than healthy controls.
They also had a longer duration of REM sleep, and less S3, S4 and SWS, but there
was no difference in REM latency.
1.6.4.  Sleep in conduct disorder
Only one PSG study of conduct disorder has been published. It was conducted by
Coble et al.(1984). The subjects in the study were pre-adolescent boys in a psychiat-
ric hospital. The age range was 8–13 years (10.9 years, SD 1.4). All the subjects had
a normal IQ and none suffered from any demonstrable medical, organic, or neuro-
logical disorder. Standard clinical waking EEGs were normal in all cases. The pri-
mary diagnosis of CD was made after a comprehensive pediatric, neurological, psy-
chiatric, psychological, and educational evaluation using the DSM III diagnostic cri-
teria. The boys had not taken any medication. Seventeen normal, healthy, age-
matched boys served as controls. The only difference between the groups was the
higher number of delta waves found in boys with CD compared with controls. As the
writers commented, the study was preliminary, but it did, however, suggest that an
abnormality in the expression of SWS may be present in at least some of the children
with CD.
1.6.5.  Diurnal activity rhythm disturbance in intermittent explosive disorder
In a study by Virkkunen et al. (1994), 20 alcoholic, impulsive offenders with IED
were studied in a forensic psychiatry ward using a wrist actigraph, which permitted
continuous recordings of activity for a period of 10 days. The subjects had indistin-
guishable day and night activity counts, a striking difference from impulsive offend-
ers with ASP, non-impulsive offenders and healthy volunteers. The result demon-
strated a profound diurnal activity rhythm disturbance associated with IED. There
are no published PSG studies in this diagnosis group.
1.6.6.  The low-arousal theory
Several studies have found abnormalities in the waking EEG of antisocial persons. In
a review of 1500 criminals, the most prominent form of waking EEG abnormality
was the presence of theta and delta activity (Ellingson, 1954). In a study of severely
aggressive individuals, the abnormality in waking EEG was localised to the temporal
19
Sleep in mental and behavioural disorders
lobes of the cerebral hemispheres. Within the group, the temporal abnormality was
more severe in the highly aggressive subjects  than the less aggressive ones (Hill,
1952). Among children with severe behavior problems including poor impulse con-
trol and inadequate socialization, the most frequent forms of waking EEG abnormal-
ity also included temporal theta and delta activity (Bayrakal, 1965). Forssman and
Frey (1953) reported that antisocial boys with behaviour problems had difficulties in
maintaining normal arousal levels during the waking EEG study.
These cortical findings as well as some autonomic findings, prompted Hare (1970) to
formulate the low-arousal theory, which accounted for many aspects of the behaviour
of antisocial persons, including impulsivity, aggressiveness, and the desire for imme-
diate gratification. Hare suggested that such person has a pathologically low level of
autonomic and cortical arousal; that he is hyporeactive compared with the normal
individual, and consequently exists in a chronic state of “stimulus-hunger”. Since the
antisocial individual is under-reactive to stimuli, which would be stressful, exciting,
or frightening to normal persons, he requires a greater variety and intensity of sen-
sory inputs to increase his arousal level to the optimum level (Mawson and Mawson,
1977).
The low-arousal theory also builds a hypothetical link between waking EEG abnor-
malities and REM sleep deficits in antisocial personality disorder. According to this
theory, the neuronal excitation of REM sleep in the second half of the night-time
sleep may serve to maintain the central nervous system at optimal levels during wak-
ing.  Antisocial persons with REM deficiency lack  this nocturnal neuronal excitation
and they may have to make up for it by obtaining massive amounts of sensory stimu-
lation during the day (Hare, 1970).
The only published PSG study of antisocial criminals was conducted in order to
clarify the role of REM sleep in this disorder (Salley and Khanna, 1980). No signifi-
cant differences in sleep parameters, including REM sleep, were observed between
the cases and the controls. However, in the study, the Rorschach content scales were
used to define the caseness, and as the writers commented, another method of diag-
nosing could have resulted in a different outcome.
1.6.7.  Neuroimaging and functional studies of brain activity predict
abnormal sleep in antisocial personality disorder
Whereas earlier studies were generally more qualitative, waking EEG technology has
become increasingly more advanced, allowing for detailed quantitative computerized
analysis in place of clinical visual inspection (Gatzke-Kopp et al., 2001). The results
of studies of  these types of studies have particularly indicated temporal and frontal
abnormalities in violent subjects (Convit et al., 1991; Wong et al., 1994). In a waking
EEG study of a forensic population (Gatzke-Kopp et al., 2001), significant increases
in slow-wave activity were found in the temporal lobes of subjects charged with
either murder or manslaughter. Unfortunately, the authors did not specify how many
of the violent offenders had ASP.
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It is problematic to extrapolate the findings from waking EEGs to PSGs.  In a study
of healthy volunteers, relationships between the spectral characteristics of the waking
and sleeping EEG within an individual were explored (Ehlers et al., 1998). Spectral
profiles in the delta, theta, alpha and beta frequency bands of a subject’s waking EEG
were found to be highly correlated with their sleep EEG. These significant correla-
tions between waking and sleep EEG made the writers suggest that the spectral signa-
ture of an individual’s EEG may be found across sleep/wake states. Finelli et al.
(2000) investigated the relationship between markers of sleep homeostasis during
waking and sleep. The EEGs of eight young males were recorded intermittently
during a 40-h wakefullness episode, as well as during baseline and recovery sleep. In
the course of extended wakefulness, the spectral power of the EEG in the theta band
(5–8 Hz) increased. In non-REM sleep, slow-wave activity (0.75–4.5 Hz) was en-
hanced on the recovery night relative to baseline. A comparison of individual records
revealed a positive correlation between the rate of increase in theta activity during
wakefullness and the increase in slow-wave activity in the first non-REM sleep epi-
sode. A topographic analysis showed that both effects were most intensive in frontal
areas. From the results, the authors suggested that theta activity in wakefulness and
slow-wave activity in sleep might be markers of a common homeostatic process. It is
possible to assume, in the light of the previous two studies, that daytime EEG abnor-
malities measured in violent subjects could also be a marker of sleep abnormalities.
The prefrontal cortex (PFC) plays a key role in the regulation of anger and violence.
Recent brain imaging studies propose a link between ASP and both structural and
functional disturbances in the PFC. A reduction in prefrontal grey matter volume in
the ASPs compared with controls in magnetic resonance imaging (MRI) was first
demonstrated by Raine et al. (2000). In  single photon emission tomography (SPET),
a reduction in prefrontal cerebral blood flow (CBF) in subjects with impulsive vio-
lent crimes has been reported (Amen et al., 1996; Söderström et al., 2000). PFC also
plays a role in maintaining of wakefulness and non-specific arousal (Horne 1993;
Dahl 1996) and profound changes in brain metabolic activity in sleep-wake transi-
tions have been shown to take place in frontal areas (Maquet et al., 1997; Balkin et
al., 2002). It is possible to assume that the PFC deficit among the ASPs would also be
reflected to their sleep.
1.7.  Sleep and alcohol
1.7.1.  Sleep in intoxicated non-alcoholics
Acute alcohol ingestion often has a transient sedative effect, especially in sleepy or
anxious individuals. It is probably the most frequently used sleeping aid in the gen-
eral population (Gillin and Drummond, 2000). In a survey of 18- to 45-year-olds in
the general population, 13 % reported using alcohol during the previous year in order
to fall asleep; an additional 5 % of the population used both alcohol and a hypnotic in
order to sleep (Johnson et al., 1998). When given to normal controls shortly before
bedtime, alcohol tends to shorten sleep latency and increase NREM sleep and to
reduce REM sleep (Yules et al., 1967). In a study by Van et al. (1995) the effects of
the ingestion of 0.64 g/kg alcohol on the structure of nap were compared with those
of a non-alcoholic drink in eight young male subjects napping between 2 pm and 3
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pm. While not affecting total nap-sleep duration, alcohol significantly increased the
time in S4 sleep, primarily at the expense of the time spent in S2. Although alcohol
increases sleep at the beginning of the night, it worsens it at the end of the night,
when the individual is likely to be in the withdrawal state. The consequence is shal-
low, disrupted sleep with increased REM sleep, dream recall or lively nightmares
(Gillin and Drummond, 2000).
1.7.2.  Sleep in alcoholics
Cloninger et al. (1981) proposed two different kinds of alcoholism. Type 1 alcohol-
ism is characterized by a late onset, more evidence of psychological dependence than
of physical dependence, and the presence of guilt feelings concerning the use of
alcohol, where as type 2 alcoholism is characterized by onset at early age, the spon-
taneous seeking of alcohol for consumption, and a socially disruptive set of behav-
iours when the person is intoxicated. Patients with type 2 alcoholism have usually
been excluded from sleep studies, so the information from sleep architecture in alco-
holism comes from studies of type 1 patients. The typical abnormalities seen in the
sleep architecture of alcoholics are increased sleep latency, poor SE, and reduced
TST, SWS and REM sleep (Benca et al., 1992). However, some tolerance develops
to REM-suppressing effects of alcohol (Gillin and Drummond, 2000). Alcohol-de-
pendent patients have been reported to have lower levels of SWS power than normal
controls (Lands, 1999).
1.7.3.  Sleep during recovery and abstinence
Disturbances in sleep continuity, delayed sleep onset, increased S1 sleep, reduced
SWS and REM sleep abnormalities have been reported after withdrawal (Williams et
al., 1981; Gillin et al., 1990; Gann et al., 2001). Mossberg et al. postulated that sleep
difficulties after acute withdrawal will last approximately four to eight weeks
(Mossberg et al., 1985). In a longitudinal study of alcoholic patients who were ini-
tially evaluated after an average of 32 days of sobriety, patients who relapsed at an
average of five months differed in both subjective and objective sleep measures from
those who remained sober. After controlling for a variety of measures, poly-
somnographic sleep latency was the best predictor of relapse (Brower et al., 1998). In
a study by Adamson et al (1973), even after one or two years of abstinence, the sleep
records of alcoholics had partly normalized, but the percentage of S4 remained at
lowered levels.
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2. AIMS OF THE STUDY
In this work, sleep macro- and micro-structure are studied in mental disorders (anorexia
nervosa and antisocial personality disorder) and during medication (olanzapine).
The aims of the present research, study by study, were:
I. To characterize the relationships between malnutrition, PSG, power spectrum of
sleep, and the hormones associated with malnutrition in patients with anorexia
nervosa before and after weight gain. The hypothesis was that the levels of growth
hormone axis hormones and leptin would be associated with sleep alterations in
these patients.
II. To characterize the sleep of habitually violent offenders with antisocial personal-
ity disorder.
III. To characterize the relationships between different categorical diagnoses describ-
ing impulsive aggression, testosterone and sleep.
IV. To study the effects of a single dose of olanzapine on sleep and its EEG spectral
power properties in healthy subjects. The hypothesis was that olanzapine would
promote sleep, possibly due to its affinity to 5-HT2 receptors, and that the re-
sponse might be different in women and men.
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3.  SUBJECTS AND METHODS
3.1.  Subjects and study design
I. GH-IGF-1 axis, leptin and sleep in anorexia nervosa patients
The subjects for the study were 11 females meeting the DSM IV criteria for restrict-
ing type anorexia nervosa (APA, 1994). Diagnoses were made by the same senior
psychiatrist using the SCID interview for DSM IV axis I disorders (First et al.,
1996). The age range was 17–28 years, mean + SEM 19.7 + 1.1 years. They were
hospitalised, and sleep examinations were performed on an open ward after the first
week of admission. The patients had no comorbid somatic disorders, assessed by the
consultant internist. The Montgomery- Åsberg Depression Rating Scale (MADRS)
was used to evaluate the degree of depression. All the subjects were drug free for at
least four weeks prior to the investigation. They did not smoke. The BMIs ranged
between 11.0 and 14.0 kg / m2 (mean + SEM 13.3 + 0.3 kg/m2) reflecting a severe
state of starvation. The mean duration of AN was 2.2 + 0.6 years.
Patients stayed on the ward for several weeks (mean + SEM 65.7 + 6.4 days). During
the treatment programme, patients received a standard hospital diet. Nutritional sup-
port was not given intravenously or enterally through a nasogastric tube at any phase
of the treatment. The patients‘ dietary intake was progressively increased to produce
a weight gain of 0.5–1.5 kg/week. Four patients started to use psychotropic medicine
(neuroleptics or antidepressants) during the treatment period, and two patients left
the hospital without the doctor’s permission. The study group thus consisted of five
drug-free females (mean age + SEM 21.2 + 1.8 years) during the sleep examination
after the weight gain. The BMIs of these five patients varied between 13.0 and 13.8
kg/m2 (mean + SEM 13.5 + 0.2 kg/m2) during the first sleep examination and be-
tween 15.0 and 16.0 kg/m2 (mean + SEM 15.6 + 0.2 kg/m2) during the second.
The eleven normal-weight (mean BMI + SEM 21.4 + 0.5 kg / m2) controls consisted
of hospital staff and students. They were gender- and age-matched (mean + SEM
20.9 + 0.8 years) and healthy without a history of somatic, psychiatric or neurologi-
cal disorders or substance abuse. As part of a psychiatric examination, the SCID non-
patient version (Spitzer et al., 1990) was filled in. The Eating Disorder Inventory
(EDI) was filled in by each control and it showed no signs of an eating disorder at
that time. In the interview each control described her eating habits as normal. Blood
tests (including blood count, serum amylase, thyroid function, kidney and liver func-
tion) and electrocardiograms were normal. Controls were told to avoid alcohol,
drugs or medication two weeks prior to the sleep examinations. Two of the controls
smoked; the consumption was approximately three cigarettes a day.
The regularity of sleep-wake rhythm was assessed in both anorectics and healthy
controls using sleep diaries and actigraphy for one week during the experiment pe-
riod. For the sleep examinations, the controls entered the hospital at 4 pm, and the
electrodes were attached between 4.30 pm and 5.30 pm. The controls slept in the
guest room of the hospital while anorectics slept on the ward. Both groups were
advised to continue their normal activities after the attachment of the recording elec-
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trodes, and start the EEG recording when they felt sleepy. Both patients and controls
were allowed to sleep as long as they wanted. The sleep recordings were made on two
consecutive nights. The first night was the adaptation night and only the second night
was considered for the study. The blood samples for hormone measurements were
taken at 8 am after the sleep recordings.
II. Sleep among habitually violent offenders with antisocial personality
disorder
The subjects for the study were 19 males (age range 18-49 years, mean + SEM 30.7
+ 2.58 years) with a history of recurrent violent acts. They were recruited from a
forensic psychiatric examination. All of them were charged with violent offences
(murder, manslaughter, attempted murder or manslaughter, assault). They all met the
DSM IV criteria for ASP (APA, 1994). Diagnoses were made by the same senior
forensic psychiatrist using the SCID interview for DSM IV axis I and II disorders
(First et al., 1996; First et al., 1997). The comorbid diagnoses are listed in Table 1.
Subjects with psychiatric disorders known significantly to affect sleep, including
psychosis, dementia or severe depression, were excluded (n = 4). The subjects were
otherwise healthy, but five of them had either chronic hepatitis B or hepatitis C.  The
BMIs varied between 19.1 kg/m2 and 30.6 kg/m2 (24.4 kg/m2, SEM 0.92). Sixteen of
them had a history of alcoholism; their average age when they started to use alcohol
was 13 years. Because they had been in prison before the psychiatric evaluation, they
had an abstinence period of several months (mean + SEM 4.4 + 0.41 months). In the
laboratory tests, S-GT varied between 15-68 U/L (reference values 10–60 U/L) and
S-CDT between 9–20 U/L (reference values < 20 U/L). Urine screening for illicit
drugs was performed just before the sleep examination and was negative in all cases.
Sixteen of them smoked; the consumption was approximately 20 cigarettes a day.
Brain MRI (1.5 T) disclosed no abnormality. The waking EEG was normal in 15
cases, while four subjects had a mild slowing of EEG background activity. The aver-
age IQ was low normal (mean + SEM 90.5 + 3.06). The mean duration of formal
education was 8.7 years. The subjects stopped using medication two weeks prior to
the sleep examinations.
Eleven controls were gender and age matched (age range 20-52, mean + SEM 32.5 +
3.44 years) as well as weight matched (mean BMI + SEM 25.9 + 1.22 kg/m2) and
healthy without history of somatic, psychiatric or neurological disorders or substance
abuse. As part of a psychiatric examination, the SCID non- patient version (Spitzer et
al., 1990) was filled in. To exclude structural brain abnormalities, brain MRI (1.5 T)
was performed, and, to exclude general diseases that could affect sleep, blood tests
(including serum prolactin, thyroid function, kidney and liver function) and electro-
cardiograms were taken. Seven of them smoked; the consumption was approximately
five cigarettes a day. Controls were asked to avoid alcohol, drugs or medication for
two weeks prior to the sleep examinations.
The study design was similar to that in Study I.
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III. Human impulsive aggression: a sleep research perspective
The subjects consisted of a subgroup of habitually violent offenders presented in
Study II. All 16 males met the DSM IV criteria for ASP, and, in addition six of them
also for BPD. Subjects with a  DSM IV axis I diagnosis  other than drug and alcohol
dependence were excluded (n = 2), as were subjects with an axis II diagnosis other
than the two above-mentioned  personality disorders ( n = 1). The trial records and
background information, including medical, family and criminal history from child-
hood and adolescence to adulthood, were studied. Using these data and information
from the SCID interview for DSM IV axis I and II disorders (First et al., 1996; First
et al., 1997), the severity of the preceding CD and the possible diagnosis of IED were
evaluated. The severity of the preceding CD was rated as mild (lying, truancy, stay-
ing out after dark without permission), moderate (stealing without confronting a
victim, vandalism) or severe (forced sex, physical cruelty, use of a weapon, stealing
while confronting a victim, breaking and entering) using the descriptive guidelines
of DSM IV-TR (APA, 2000). The essential features of IED (the occurrence of dis-
crete episodes of failure to resist aggressive impulses that result in serious assaultive
acts or destruction of property = criterion A and the degree of aggressiveness ex-
pressed during an episode is grossly out of proportion to any provocation =criterion
B) were evaluated and, in cases in which both criteria were met, the diagnosis of IED
was made. In the case of one subject, not enough information was available to decide
whether or not he had IED.  All the diagnoses were made by two senior forensic
psychiatrists with no knowledge of the results of the sleep examination. The blood
samples for hormone measurements were taken at 8 am after the sleep recordings.
The distribution of subjects to different clinical diagnosis groups and the overlap in
the distribution can be seen in Table 2.  The subjects had alcohol abstinence of
several months (mean + SEM 4.8 + 0.41 months). The waking EEG was normal in
13 cases, while three subjects had mild slowing of EEG background activity.
The control group consisted of the same eleven persons described in Study II.
For sleep assessment, the sleep recordings in Study II were used.
Table 1. The comorbid DSM IV psychiatric diagnosis among 19 males with antisocial person-
ality disorder
301.7 ANTISOCIAL PERSONALITY DISORDER
303.90 alcohol dependence 16
304.10 anxiolytic dependence 6
304.4 amphetamine dependence 5
304.30 cannabis dependence 5
301.0 paranoid personality disorder 1
301.83 borderline personality disorder 7
300.01 panic disorder without agoraphobia 1
300.21 panic disorder with agoraphobia 1
300.4 dysthymic disorder 2
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IV. Effect of a single-dose of olanzapine on sleep in healthy females and males
Seventeen healthy volunteers consisting of hospital staff and students participated in
the study. Four of the 17 were excluded from the study because of technical failure
(one), sedative medication by chance (one), abnormally high prolactin level (one)
and an acute somatic disease during the recording procedure (one). So the study
comprised seven men and six women (mean age + SEM 25.3 + 2.1 years versus 33.2
+ 3.0 years; t (12) = –2.214, p = 0.05). The mean body weights were + SEM 77.9 +
2.0 kg in males and 70.8 + 5.8 kg in females; t (12) = –1.2, p = 0.245 and the mean
BMIs were + SEM 24.9 + 0.8 kg/m2 in males and 25.1 + 1.8 kg/m2 in females; t (12)
= –0.09, p = 0.932.  The subjects were asked to avoid alcohol, drugs or medication
for two weeks prior to the sleep examinations. Eight of them smoked; the consump-
tion was approximately 5 cigarettes a day. As part of a psychiatric examination, the
SCID non-patient version (Spitzer et al., 1990) was filled in. To exclude structural
brain abnormalities, brain MRI (1.5 T) was performed. Blood tests (including serum
prolactin, thyroid function, kidney and liver function) and electrocardiograms were
taken in order to exclude general diseases that could affect sleep. To exclude even
mild forms of neuropsychiatric disorders, neurological examinations, including
Barnes scale for akathisia, and the Abnormal Involuntary Movement Scale (AIMS)
and Angus-Simpson scales for extrapyramidal symptoms, were made.
The study design was similar to that in Study I, except that three recordings were made:
the adaptation night, the baseline night and the night following 10 mg of olanzapine
administered at 6 pm, with placebo administered for the first and second recording
nights. The participants were informed that on one of the three recording nights they
would be given olanzapine and in other two nights placebo. The initial dose of
Table 2.  The overlap of different diagnostic subgroups among 16 male offenders.
ASP = antisocial personality disorder, BPD = borderline personality disorder, CDs = conduct disorder
type severe, CDm = conduct disorder type mild or moderate, IED+ = intermittent explosive disorder,
IED- = no intermittent explosive disorder
subject age index crime ASP BPD CDs CDm IED+ IED-
1 19 attempted manslaughter × ×
2 46 attempted manslaughter × × ×
3 27 murder × × ×
4 18 assault × × ×
5 34 attempted manslaughter × × ×
6 27 attempted manslaughter × × ×
7 40 manslaughter × × × ×
8 45 manslaughter × × ×
9 39 manslaughter × × × ×
10 39 manslaughter × × × ×
11 23 assault × × × ×
12 20 murder × × × ×
13 48 attempted manslaughter × × × ×
14 29 manslaughter × × ×
15 20 murder and attempted
manslaughter × × ×
16 18 attempted manslaughter × × ×
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olanzapine in the treatment of schizophrenia is usually 10 mg once a day (Beasley et al.,
1997; Nyberg et al., 1997), and this dose was also chosen for the study.
3.1.1.  Overlap of control samples
Three healthy women volunteers, who participated in Study IV also served as controls
in Study I. Among the men, seven healthy volunteers, who participated in Study IV
also served as controls in Studies II and III. In all, the material consisted of 25 healthy
volunteers, 11 anorectics ( five of them also after weight gain) and 19 prisoners.
3.2.  Methods
3.2.1.  Polysomnography
Sleep EEG was recorded using a mobile recording unit ( Medilog 4–24 recorder,
Oxford Medical Systems, UK) allowing the subjects to move freely in the hospital.
EMG surface electrodes were placed beneath the chin, EOG electrodes according to
Rechtschaffen-Kales standards (Rechtschaffen and Kales, 1968). During normal
sleep, the theta band has occipital dominance (Werth et al., 1997; Finelli et al.,
2001), indicating that the detection of changes in theta power is most sensitive from
EEG derivations over this area. As we wanted to maximise the detection of theta
power, an occipital derivation was chosen for recording. Right-handed persons were
recorded on derivation O2-P4 and left-handed persons on derivation O1-P3, accord-
ing to the 10–20 system. The sampling frequency was 50 Hz, and the signal was
attenuated using a first-order 6 dB/octave filter. The low- and high- pass filter fre-
quencies were 25 Hz and 0.25 Hz respectively. The signal was analysed with a Night-
ingale sleep analyzator (Judex AB, Copenhagen, Denmark). As the derivation devi-
ates from the standard C4-A1 arrangement created by Rechtschaffen- Kales, we care-
fully calibrated the signal by comparing it with the signal obtained from the standard
derivation C4-A1. Electrodes were attached to locations O2-P4 and C4-A1, and the
signals from these channels were compared. The wave forms from both channels
were similar, but the amplitude from the derivation O2-P4 was lower. The amplitude
relationship (amplification 50 microV/cm on both channels) of the signal in the C4-
A1 vs. O2-P4 derivation was compared in five SWS episodes from three subjects: the
amplitudes of four subsequent waves per episode were measured and their relation-
ship (C4-A1 per O2-P4) was calculated. The mean of these relationships was 2.282 +
0.0481 / 1. Between the subjects, the range was from 2.175 + 0.0664 / 1  to  2.420 +
0.0905 / 1. On the basis of these results, we modified the 75 microV delta wave
amplitude criterion used in the Rechtschaffen-Kales manual to 33 microV. The rest
of the scoring criterion remained the same. When this modified amplitude criterion
was applied to scoring of the signal from the O2-P4 derivation (three subjects) and
compared with scoring obtained from the same runs from the C4-A1 derivation, a
correlation of 97.8 + 0.1 for waking, 74.9 + 12.0 for stage 1, 93.9 + 0.6 for stage 2,
80.1 + 4.9 for stage 3, 88.8 + 3.7 for stage 4 and 88.2 + 6.3 for REM was obtained
by the same scorer. For comparison, the corresponding correlations between three
repeated scorings of the same file (C4-A1 derivation) by the same scorer were: wak-
ing 93.6 + 2.0, S1 81.1 + 6.9, S2 90.0 + 2.6, S3 81.5 + 7.8, S4 91.2 + 3.0 and REM
92.3 + 3.4. All the data for the analysis were scored by the same scorer. Data from the
adaptation nights were always omitted from the analysis.
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3.2.2.  Spectral power analysis
The EEG-signal was analysed after Fast Fourier transformation in five frequency
bins (band widths: delta: 0.5–3.5 Hz, theta: 3.5–8.0 Hz, alpha: 8.0–12.0 Hz, sigma:
12.0–14.5 Hz and beta: 14.5–25.0 Hz), separately for stages 2, 3, and 4. The spectral
powers in the delta and theta bins were normalized in each recording to the total
power in stages 2 + 3 + 4 to enable comparisons between different recordings for
each person and recordings between persons. SWS is most prominent during the first
hours of sleep, when delta power is also at its highest (Borbély, 1982). In studies I, II,
and IV, the SPA was focused on this particular period and analysed 480 epochs (4 hrs)
of sleep after the appearance of the first five or more consecutive epochs of stage 2
sleep onwards. In study III, both the first half and the whole night were analysed.
Results are given as percentage amounts of the given frequency bin of the total power
of the studied period.
We also compared the power values obtained from the two derivations in different
bands. Three EEG runs with both derivations were obtained, and scored according to
Rechtschaffen-Kales-criteria from the C4-A1 derivation. Spectral power was calcu-
lated for delta, theta, alpha, sigma and beta bands in stages 2 + 3 + 4 in both deriva-
tions. When compared with the C4-A1 derivation (= 100%), the power of the O2-P4
derivation was 92.9 + 5.3 % in delta, 118.2 + 8.5 % in theta, 129.0 + 13.1 % in
alpha, 81.3 + 5.1 % in sigma and 93.0 + 5.1 % in the beta band.
3.2.3.  Actigraphy
A wrist-worn actigraph (the Mini Motionlogger Actigraph, Basic Version, Ambula-
tory Monitoring Inc., New York, USA) was used. Analyses were conducted in one-
minute epochs in the zero-crossing mode, sampling rate 10 Hz, filters were either 0
or 18 (interval device code) with equal results according to the manufacturer for
sleep scoring. Sleep was defined with an algorithm by Sadeh (Sadeh et al., 1994) and
commercial software (Action-W, version 1.26) was used for analysis. For the sake of
convenience, subjects were allowed to choose the location of the actigraph on either
the  dominant or non-dominant hand. This makes a comparison between the absolute
amount of activity in sleep and wakefulness unreliable between individuals but gives
an accurate and comparable time for transitions between wakefulness and sleep
(Sadeh et al., 1994). The wrist actigraphs were used to ensure that the subjects did
not take naps during  the daytime.
3.2.4.  Hormone assays
Leptin (I) was quantitated with a radioimmunoassay (RIA) from Linco Research
Inc., St. Charles, MO, USA. The detection limit of the assay is 0.5 microg/L. Intra-
assay coefficient of variation (CV) is  < 5 % in the concentration range 7–25 microg/
L. Inter-assay CV is < 7% in the concentration range of 5–25 microg/L. The refer-
ence values are 7.4 + 3.7 microg/L in women and 3.8 + 1.8 microg/L in men.
IGF-1 (I) was quantitated with RIA from Incstar, Stillwater, MN, USA. Prior to the
assay, the serum was acidified, extracted with an ODS-silica column eluted with
methanol, which was evaporated. After reconstitution, RIA was performed on the
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residue. The detection limit of the assay is 2 nmol/L. Intra-assay CV is < 10 % in the
concentration range 9–33 nmol/L. Inter-assay CV is 13% at 9 nmol/L, 10 % at 17
nmol/L and 15 % at 33 nmol/L. The reference values are 12-48 nmol/L in women
and 9-46 nmol/L in men.
GH (I) was quantitated with a time-resolved immunofluorometric assay (Auto
DELFIA(tm), Wallac, Turku, Finland). The assay is calibrated against the WHO 1st
IRP 80/505. The detection limit is 0.03 mU/L (conversion factor 1 microg = 1 mU).
Intra-assay CV is 5 % at 0.4 mU/L and 2 % in the concentration range 5–21 mU/L.
Corresponding figures for total CV is 6 %  and 3 %, respectively. The reference
values are 0–11 mU/L.
Testosterone (III) was quantitated with a coated-tube radioimmunoassay (Spectria,
Orion Diagnostica, Espoo, Finland). The detection limit of the assay is 0.1 nmol/L.
Intra-assay CV is < 8 % at 1.6–27 nmol/L. Inter-assay CV is 7% at 1.2 nmol/L and
about 5% in the concentration range of 4–23 nmol/L. The reference values are 10–38
nmol/L in men, and 0.9–2.8 nmol/L in women.
3.2.5.  Basic Nordic Sleep Questionnaire (BNSQ)
The subject’s experience of sleep quality during the past three months (II) was as-
sessed using a standardized questionnaire developed by the Scandinavian Sleep Re-
search Society (Partinen and Gislason, 1995). The BNSQ contains a total of 21 ques-
tions, and 15 of which have a five-point quantitative scale (min 15, max 70 points).
3.2.6.  Sleep diary
Sleep diaries were used during the study period to ensure a normal sleep-wake cycle
and to exclude the effect of sleep deprivation (I–IV). Participants filled in the time of
retiring to bed, estimated time of falling asleep, and the time of awakening in the
morning for each consecutive night, respectively.
3.2.7.  Assessment scales
The Beck Depression Inventory (BDI) (Beck et al., 1961) was used to evaluate the
degree of depression (II, III, IV) as well as the Montgomery-Åsberg Depression
Rating Scale (MADRS) (Montgomery and Åsberg, 1979) (I). The Eating Disorder
Inventory (EDI) (Garner, 1991) was used to assess eating disorder symptoms (I). The
Barnes Akathisia Scale (Barnes, 1989) was used to assess clinical akathisia symptoms
(IV).  The Abnormal Involuntary Movement Scale (AIMS) (Smith et al., 1979) and
the Angus-Simpson scale (Simpson and Angus, 1970) were used to rate extrapyrami-
dal symptoms (IV).
3.3.  Statistics
I. The results for healthy controls and 11 anorectics were compared  using either a t-
test (normally distributed values) or the Mann-Whitney rank sum test (non-normally
distributed values). The parameters in the subgroup of five anorectics before and
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after weight gain were compared using a  paired t-test (all values were normally
distributed). The results for controls, and anorectics before and after weight gain
were compared using one-way ANOVA with  the post-hoc Student-Newman-Keul’s
test (normally distributed values) or Kruskal-Wallis ANOVA on ranks with the post-
hoc Dunn‘s test (non-normally distributed values). Within the groups, the correla-
tions were made using the Pearson product moment correlation (normally distributed
values) or the Spearman rank order correlation (non-normally distributed values).
II. The results were compared using either a t-test (normally distributed values) or
the Mann-Whitney rank sum test (non-normally distributed values). Inside the
groups, the correlations were made using the Pearson product moment correlation
(normally distributed values) or the Spearman rank order correlation (non-normally
distributed values).
III. The results for different subgroups of subjects with impulsive aggression and
healthy controls were compared using either one-way ANOVA with the post-hoc
Student-Newman-Keul’s method (normally distributed values) or the Kruskal-Wallis
ANOVA on ranks with the post-hoc Dunn‘s method (non-normally distributed val-
ues). One-way analysis of covariance with age as an independent factor was per-
formed for the following parameters: S4%, SWS%, delta power in stages 4 and 3+4,
theta power in stages 4 and 3+4, and serum testosterone level measurements. When
covariance should effect, the final analysis was performed using age-adjusted values.
IV.  Absolute and relative durations of sleep stages and the magnitude of delta and
theta power before and after the administration of olanzapine were compared using
either a paired t-test (normally distributed values) or Wilcoxon signed rank test (non-
normally distributed values).
3.4.  Ethics
All the studies were approved by the ethics committee at the Helsinki University Hos-
pital. Informed consent was obtained from all the participants and, in the case of one
AN patient under 18 years of age,  informed consent was also obtained from her par-
ents. It was underlined that the patients (I) and prisoners (II and III) could withdraw at
any time from the study period with no negative consequences for their treatment or
statements to the Finnish National Board of Medico-Legal Affairs (II and III).
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4.  RESULTS
The results are expressed as the mean ± SEM (I–IV).
I. GH-IGF-1 axis, leptin and sleep in anorexia nervosa patients
General conditions: The mean BMI in the AN patients was significantly lower than
in the controls (Table 3. and Fig. 1.). During the treatment period, the mean BMI
increased significantly (Table 3. and Fig. 2.) although anorectics still remained un-
derweight as compared with controls (one-way ANOVA: F (2,18) = 72.558; p<
0.001, post-hoc Student-Newman-Keul’s controls vs. anorectics before weight gain q
= 15.635, p< 0.001; controls vs. anorectics after weight gain q = 11.313, p< 0.001).
The Montgomery- Åsberg Rating Scale expressed mild depressive symptoms in all
anorexia nervosa- groups, while controls were almost symptom free (Table 3.).
PSG:  For details of the PSG, see Table 3., Fig. 1. and Fig. 2. Anorectics had
significantly less TST, AST and SWS than healthy controls. They also had more S1
sleep. No significant differences were observed in any REM parameters between
anorectics and controls. In the subgroup of five anorectics, the SWS increased sig-
nificantly after weight gain, while both S1 and S2 decreased, but there were no
differences in REM sleep parameters. With refeeding, both S1% (one-way ANOVA:
F (2,18) = 5.481; p = 0.01, post-hoc Student-Newman-Keul’s controls vs. anorectics
before weight gain q = 4.180, p< 0.009; controls vs. anorectics after weight gain q =
0.698, p = NS), and SWS% (one-way ANOVA: F (2,18) = 4.303; p = 0.03, post-hoc
Student-Newman-Keul’s controls vs. anorectics before weight gain q = 2.803, p =
0.04; controls vs. anorectics after weight gain q = 2.029, p = NS) normalized to the
levels of healthy controls.
SPA:  For details of the SPA, see Table 3., Fig. 1. and Fig. 2.. The relative delta
power during the first four hours of sleep did not differ significantly between
anorectics and healthy controls, although a tendency towards higher delta power
values in deep sleep stages was observed among controls. The weight gain did not
change the delta power significantly, although a tendency towards an increase after
weight gain was once again observed. The theta power was significantly higher in
stages 4 and 3+4 among controls. The theta power increased significantly among AN
patients after weight gain in stage 3+4.
Hormone levels: Plasma GH levels did not differ significantly between the
anorectics and the controls, and the weight gain did not affect the levels significantly.
However, a tendency towards higher GH levels in the controls, and in the anorectics
after weight gain was observed (Table 3., Fig. 1. and Fig. 2.). In anorectics both
IGF-1 levels and leptin levels were reduced compared with controls (Table 3.,
Fig.1.). In a subgroup of five anorectics, both parameters increased significantly
during weight gain (Table 3., Fig. 2.). IGF-1 increased to the levels of controls
(Kruskal-Wallis ANOVA on ranks: H (2,18)= 8.113; p = 0.02, post-hoc Dunn’s
method controls vs. anorectics before weight gain Q = 2.817, p < 0.05; controls vs.
anorectics after weight gain Q = 0.606, p = NS), while leptin still remained lower
than in controls (one-way ANOVA: F (2,18) = 13.191; p< 0.001 post-hoc Student-
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Neuman-Keul’s controls vs. anorectics before weight gain q = 6.516, p < 0.001;
controls vs. anorectics after weight gain q = 5.085 p = 0.002).
In anorectics, a negative correlation was found between S1 sleep and plasma leptin
levels (Spearman r = –0.706, p = 0.02). The study also showed a positive correlation
between plasma leptin levels and theta power both in stage 4 (Spearman r = 0.632, p
= 0.04) and in stage 3+4 (Spearman r = 0.742, p = 0.01) among patients with AN.
After weight gain, a positive correlation was seen between BMI and TST (Pearson r
= 0.892, p = 0.04). In healthy controls, the BMI correlated positively with SWS
(Pearson r = 0.742, p = 0.02) and SWS% (Pearson r = 0.862, p = 0.003), while in
anorectics this correlation was lacking.
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Table 3. The results in polysomnography, power spectral analysis and hormone assays in females with anorexia nervosa and healthy controls. CO= controls, AN=
eleven anorectics, AN1= five anorectics before weight gain, AN2= five anorectics after weight gain, BMI = body mass index, MADRS = Montgomery-Åsberg
Depression Rating Scale, GH = growth hormone, IGF-1 = insulin-like growth factor 1, TST = total sleep time, AST = actual sleep time, SE = sleep efficiency, S1-S4
= sleep stages 1-4, SWS = slow wave sleep, REM = rapid eye movement sleep, NS= change/difference is not statistically significant, * = non-normally distributed
values. Comparisons were made using a t-test (normally distributed values), Mann-Whitney rank sum test (non- normally distributed values), and paired t-test (all
values normally distributed). All values expressed as mean + SEM.
CO AN CO vs AN AN1 AN2 AN1 vs AN2
n = 11 n = 11 t p n = 5 n = 5 t p
df = 20 df = 9
BMI 21.4 + 0.53 13.3 + 0.30 13.383 <0.001 13.5 + 0.20 15.7 + 0.19 –6.248 0.003
MADRS 1.8 + 0.60 9.3 + 0.98 –6.475 <0.001 8.0 + 1.10 6.4 + 0.98 1.425 NS
hormones
GH 0.3 + 0.10 0.2 + 0.06 1.185 NS* 0.1 + 0.02 0.3 + 0.20 –1.054 NS
IGF-1 31.7 + 2.88 23.3 + 1.80 2.486 0.02 20.2 + 1.07 25.6 + 1.33 –3.762 0.02
leptin 16.3 + 2.40 1.2 + 0.17 6.285 <0.001* 1.2 + 0.16 4.5 + 1.25 –2.676 0.04
polysomnography
TST (min) 549.3 + 19.70 479.5 + 15.06 2.818 0.01 480.2 + 22.59 454.6 + 37.58 0.823 NS
AST (min) 532.6 + 18.73 446.9 + 17.41 3.354 0.003 453.6 + 27.89 445.1 + 36.23 0.244 NS
SE (%) 97.0 + 0.51 93.1 + 1.73 2.178 0.04 94.1 + 1.85 97.9 + 0.38 –2.369 NS
sleep latency (min) 12.2 + 2.88 9.1 + 1.53 0.948 NS 7.1 + 1.76 25.9 + 12.94 –1.363 NS
S1 (min) 17.9 + 3.24 34.1 + 5.49 2.546 0.02 27.1 + 3.85 12.1 + 2.26 4.064 0.02
S1 (%) 3.2 + 0.56 7.6 + 1.12 –3.476 0.002 5.9 + 0.71 2.8 + 0.61 3.117 0.04
S2 (min) 285.0 + 17.03 243.5 + 20.53 1.557 NS 255.2 + 33.70 225.8 + 25.66 3.081 0.04
S2 (%) 53.3 + 1.93 56.5 + 2.41 –1.067 NS 58.5 + 3.00 50.3 + 2.71 5.215 0.006
SWS (min) 113.1 + 5.78 73.6 + 11.49 3.070 0.006 88.6 + 19.20 113.0 + 13.20 –2.634 NS
SWS (%) 21.4 + 1.28 15.0 + 2.31 2.434 0.02 15.7 + 2.98 25.5 + 2.82 –5.199 0.007
REM latency (min) 87.2 + 8.35 106.6 + 12.50 –1.289 NS 120.2 + 22.26 96.6 + 20.22 1.028 NS
REM (min) 116.7 + 8.67 91.8 + 8.01 2.110 NS 86.4 + 11.39 94.5 + 12.62 –0.461 NS
REM (%) 21.9 + 1.51 20.7 + 1.77 0.509 NS 19.7 + 3.23 21.1 + 2.37 –0.507 NS
spectral power analysis
thetapower %
stage 3 6.1 + 1.18 5.3 + 0.86 0.481 NS 3.7 + 0.80 4.4 + 1.00 –1.591 NS
stage 4 9.8 + 1.42 5.8 + 1.15 2.166 0.04 8.4 + 3.28 11.2 + 1.79 –2.609 NS
stage 3+4 15.9 + 0.97 11.2 + 1.14 3.109 0.006 12.1 + 1.65 15.6 + 2.57 –2.816 0.05
stage 2+3+4 30.6 + 1.59 30.2 + 1.52 0.187 NS 28.8 + 2.57 28.6 + 2.60 0.148 NS
deltapower %
stage 3 5.0 + 0.95 5.5 + 1.26 –0.285 NS 4.3 + 1.42 4.1 + 0.42 0.190 NS
stage 4 11.8 + 1.83 8.4 + 2.23 1.173 NS 13.0 + 3.43 15.3 + 2.07 –1.464 NS
stage 3+4 16.8 + 1.33 13.9 + 2.53 1.026 NS 17.3 + 3.23 19.4 + 1.77 –1.057 NS
stage 2+3+4 26.4 + 2.13 25.0 + 2.89 0.395 NS 29.0 + 2.89 27.9 + 1.98 0.486 NS
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Figure 1. Results for polysomnography, spectral power analysis and hormone assays in 11 healthy
controls (CON) and 11 women with anorexia nervosa (AN). Comparisons were made using either a
t-test (normally distributed values) or Mann-Whitney rank sum test (non-normally distributed values).
BMI = body mass index, GH = growth hormone, IGF-1 = insulin-like growth factor 1, S1 = sleep
stage 1, SWS = slow wave sleep, ST = stage.
* = p < 0.05, ** = p < 0.01, *** = p < 0.001
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Figure 2. Results for polysomnography, spectral power analysis and hormone assays before (AN1)
and after weight gain (AN2) in 5 women with anorexia nervosa. Comparisons were made using paired
t-test (all values normally distributed). BMI = body mass index, GH = growth hormone, IGF-1 =
insulin-like growth factor 1, S1 = sleep stage 1, SWS = slow wave sleep, ST = stage.
* = p < 0.05, ** = p < 0.01, *** = p < 0.001
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II. Sleep among habitually violent offenders with antisocial personality
disorder
BNSQ: The ASP individuals scored more total points on the BNSQ than the controls
(35.3 + 3.31 vs. 21.8 + 2.27, t (28) = –2.868, p = 0.008), reflecting an impairment in
subjective sleep quality. They tended to have more problems in falling asleep, they
reported more awakenings during the night, they felt more sleepy in the mornings
and they also reported more naps during the daytime than the controls.
PSG: For details of the PSG, see Table 4. and Fig. 3. There was no significant
difference in TST or AST between the groups. ASP individuals had significantly
more awakenings during the night, and as a result, SE in ASP was lower than in the
controls. No difference in sleep latency was observed. In S1, there was no significant
difference between the groups, but the percentage amount of S2 was significantly
higher in the controls. The percentage amount of SWS was significantly higher in
ASP because the percentage of S4 in deep sleep was extremely emphasized. There
were no differences in any REM sleep parameters between the groups. The negative
correlation between age and SWS was found among both controls (for SWS%:
Pearson r = –0.479, p = 0.04 and for S4%: Pearson r = -0.617, p = 0.005) and ASPs
(for SWS % :Pearson r = –0.635, p = 0.004 and for S4%: Pearson r = -0.606, p =
0.006).
SPA: For details of the SPA, see Table 4. and Fig. 3. Both theta and delta power
differed significantly between ASP and controls. Theta power was higher in controls
in both S2 and S3, but in S4 the opposite finding was made: in this stage, theta power
was much higher in ASP. Delta power was significantly higher in controls in S3, but
in S4, S3+4 and S2+3+4 delta power was much higher in ASP.
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Table 4. Results for polysomnography and spectral power analysis in 19 habitually violent
offenders with antisocial personality disorder (ASP) and 11 healthy controls (CO). TST = total
sleep time, AST = actual sleep time, SE = sleep efficiency, S1-S4 = sleep stages 1–4, SWS = slow
wave sleep, REM = rapid eye movement sleep, NS = difference is not statistically significant, NP =
non-normally distributed values. Comparisons were made using a t-test (normally distributed values)
or Mann-Whitney rank sum test (non-normally distributed values). All values expressed as mean +
SEM.
ASP CO tp
n = 19 n = 11 df = 28
polysomnography
TST (min) 455.8 + 17.22 461.0 + 21.47 –0.213 NS
AST (min) 421.1 + 14.33 442.6 + 22.61 –0.847 NS
SE (%) 92.7 + 1.22 95.7 + 1.51 –1.526 0.03 NP
awakenings (n) 18.7 + 2.17 11.7 + 1.26 2.300 0.03
sleep latency (min) 28.8 + 7.93 18.5 + 6.99 0.885 NS NP
S1 (min) 26.2 + 3.59 23.3 + 5.38 0.454 NS NP
S1 (%) 6.6 + 0.83 5.3 + 1.15 0.963 NS NP
S2 (min) 187.5 + 14.83 228.7 + 11.91 –1.907 NS
S2 (%) 45.5 + 1.50 51.8 + 1.33 –2.822 0.009
S3 (min) 37.2 + 3.07 63.5 + 5.75 –4.438 <0.001
S3 (%) 8.9 + 0.79 14.6 + 1.40 –3.879 <0.001
S4 (min) 71.6 + 7.48 24.9 + 4.29 4.485 <0.001
S4 (%) 17.2 + 1.80 6.3 + 0.96 4.349 <0.001
SWS(min) 108.7 + 6.74 88.4 + 7.56 1.921 NS
SWS (%) 26.0 + 1.62 21.0 + 1.31 2.141 0.04
REM-latency (min) 97.3 + 10.76 105.3 + 16.75 –0.421 NS NP
REM(min) 90.7 + 4.26 98.4 + 9.69 –0.835 NS
REM (%) 21.6 + 0.92 21.8 + 1.32 –0.0885 NS
spectral power analysis
theta power (%)
stage 2 11.7 + 0.94 17.3 + 1.17 –3.733 <0.001
stage 3 3.8 + 0.42 8.9 + 0.75 –6.478 <0.001
stage 4 12.0 + 0.91 4.6 + 0.67 5.742 <0.001
stage 3+4 15.8 + 0.79 13.4 + 1.01 1.823 NS
stage 2+3+4 27.0 + 1.23 30.8 + 1.59 –1.901 NS
delta power (%)
stage 2 7.8 + 0.78 7.2 + 0.79 0.473 NS
stage 3 3.1 + 0.37 5.8 + 0.55 –4.097 <0.001
stage 4 18.3 + 2.99 4.5 + 0.94 3.436 0.002
stage 3+4 21.2 + 3.02 10.2 + 1.24 2.663 0.01
stage 2+3+4 29.0 + 3.15 17.4 + 1.79 2.636 0.01
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Figure 3. Results for polysomnography and spectral power analysis in 19 antisocial violent offenders
(ASP) and 11 controls (CO). Comparisons were made using a t-test (all values normally distributed).
SWS = slow wave sleep, S4 = sleep stage 4, ST = stage.
* = p < 0.05, ** = p < 0.01, *** = p < 0.001
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III. Human impulsive aggression: a sleep research perspective
Antisocial vs. antisocial with comorbid borderline personality disorders:
General: There was no significant difference in age between the subject groups and
healthy volunteers (antisocials 28.1 + 3.40 years vs. antisocials with BPD
comorbidity 34.8 + 4.45 years vs. controls 32.5 + 3.44 years; one-way ANOVA:
F(2,24) = 0.793, p = NS). The BDI scores expressed mild depressive symptoms in
both subject groups without significant differences between groups, while the con-
trols were almost symptom free (antisocials 10.6 + 2.18 vs. antisocials with BPD
comorbidity 12.0 + 2.35 vs. controls 1.6 + 0.78; one-way ANOVA: F(2,24) =
10.789, p < 0.001, post-hoc Student-Newman-Keul’s  antisocials vs. antisocials with
BPD comorbidity q = 0.731, p = NS, antisocials vs. controls q = 5.529, p < 0.001,
antisocials with BPD comorbidity vs. controls  q = 5.503, p = 0.002).
Polysomnography: For details of the polysomnography, see Table 5. and Fig. 4.
Antisocials with BPD comorbidity had significantly more awakenings during the
night, and, as a result, SE in this subgroup was significantly lower compared with
both the ASP-group and controls. Both subgroups had significantly higher absolute
and percentage amounts of S4 sleep compared with controls but there were no statis-
tically-significant differences between subgroups. The absolute and percentage
amounts of S3 sleep were lower in both subgroups compared with controls but again
there was no statistically- significant difference between subgroups.
Spectral power analysis: For details of the spectral power analysis, see Table 6.
and Fig. 4. During the first half of the sleep period, there were no statistically-
significant differences between the subgroups in theta and delta power in stages 4 and
3+4. The ASP-group had higher theta power in stage 4 and delta power in stages 4
and 3+4 compared with controls. The antisocials with BPD comorbidity had higher
theta power in stage 4 compared with controls. During the whole sleep period, there
were no statistically-significant differences between the subgroups. The APD-group
had higher theta and delta power in stages 4 and 3+4 compared with controls. The
antisocials with BPD had higher theta and delta power in stage 4 compared with
controls.
Serum testosterone levels: The serum testosterone levels of  “pure” antisocials were
mean + SEM 20.6 + 2.66 nmol/L and the serum testosterone levels of antisocials with
BPD comorbidity were 20.4 + 1.74 nmol/L. There were no significant differences
between the age-adjusted serum testosterone levels of antisocials without and with
BPD comorbidity (mean + SEM 21.9 + 0.88 nmol/L vs. 19.6 + 0.45 nmol/L; F
(1,14) = 0.664, p = NS).
Severe conduct disorder vs. mild or moderate conduct disorder:
General: There was no significant difference in age between the subject groups and
healthy volunteers (CD type severe 27.8 + 3.81 years vs. CD mild/ moderate 33.5 +
3.92 years vs. controls 32.5 + 3.44 years; one-way ANOVA: F(2,24) = 0.631, p =
40
Sleep in mental and behavioural disorders
NS). The BDI scores expressed mild depressive symptoms in both subject groups
without significant differences between groups, while the controls were almost
symptom free (CD type severe 11.6 + 2.60 vs. CD type mild/moderate 10.6 + 1.98
vs. controls 1.6 + 0.78; one-way ANOVA: F(2,24) = 10.674, p < 0.001, post-hoc
Student-Newman-Keul’s  CD type severe vs. CD type mild/moderate q = 0.538, p =
NS, CD type severe vs. controls q = 5.778, p = 0.001, CD type mild/moderate vs.
controls q = 5.200, p = 0.001).
Polysomnography: For details of the polysomnography, see Table 5. and Fig. 4.
The subgroup with preceding type severe CD had significantly higher absolute and
percentage amounts of S4 sleep and SWS but less S2 sleep compared with those
subjects with only mild or moderate CD and controls. Both subgroups had lower
absolute and percentage amounts of S3 sleep compared with controls, but there was
no statistically- significant difference between subgroups.  The group with mild or
moderate CD had significantly higher absolute and percentage amounts of S4 sleep
compared with controls.
Spectral power analysis: For details of the spectral power analysis, see Table 6.
and Fig.4. During the first half of the sleep period, the subgroup with preceding type
severe CD had higher theta and delta powers in stages 4 and 3+4 compared with men
with mild or moderate CD and controls. The subgroup with preceding type mild or
moderate CD had higher theta power in stage 4 compared to controls. During the
whole sleep period, the subgroup with preceding type severe CD had higher theta and
delta power in stages 4 and 3+4 compared with men with mild or moderate CD and
controls. The subgroup with preceding type mild or moderate CD had higher theta
and delta power in stage 4 compared with controls.
Serum testosterone levels: The serum testosterone levels of the group with preced-
ing type severe CD were mean + SEM 24.1 + 1.83 nmol/L and the serum testosterone
levels of the group with preceding type mild or moderate CD were16.9 + 1.27 nmol/
L. The group with preceding type severe CD had significantly higher age-adjusted
serum testosterone levels than those with only mild or moderate CD (mean + SEM
23.5 + 0.52 nmol/L vs. 17.4 + 0.52 nmol/L; F (1,14) = 2.882, p = 0.01).
Intermittent explosive disorder vs. no intermittent explosive disorder:
General: There was no significant difference in age between the subject groups and
healthy volunteers (IED+ 28.5 + 3.36 years vs. IED- 37.2 + 4.41 years vs. controls
32.5 + 3.44 years; one-way ANOVA: F (2,23) = 1.106, p = NS). The BDI scores
expressed mild depressive symptoms in both subject groups without significant dif-
ferences between groups, while the controls were almost symptom free (IED+ 12.6 +
2.00 vs. IED- 10.0 + 2.55 vs. controls 1.6 + 0.78; one-way ANOVA: F (2,23) =
13.824, p < 0.001, post-hoc Student-Newman-Keul’s IED+ vs. IED- q = 1.364, p =
NS, IED+ vs. controls q = 7.211, p < 0.001, IED- vs. controls q = 4.456, p = 0.005).
Polysomnography: For details of the polysomnography, see Table 5. and Fig. 4.
The only statistically- significant differences in sleep parameters between males with
IED and males without this diagnosis were found in S4 sleep and in SWS, with
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higher absolute and percentage amounts of S4 sleep and absolute amount of SWS in
men with IED. The absolute and percentage amounts of S4 sleep and absolute
amount of SWS were higher in men with IED compared with controls, while abso-
lute and percentage amounts of S3 sleep were lower.  The absolute amount of S3
sleep was significantly decreased in men without IED compared with controls.
Spectral power analysis: For details of the spectral power analysis, see Table 6.
and Fig. 4. During the first half of the sleep period, the subgroup with IED had
higher theta power in stages 4 and 3+4 and delta power in stage 4 compared with men
without this diagnosis. The subgroup with IED had higher theta and delta power in
stages 3 and 3+4 compared with controls.  There were no statistically-significant
differences between subjects without IED and controls. During the whole sleep pe-
riod, the subgroup with IED had higher theta and delta power in stage 4 compared
with men without the diagnosis. The subgroup with IED had higher theta power in
stage 4 and delta power in stage 4 and 3+4 compared with controls. The subgroup
without IED had higher theta and delta power in stage 4 compared with controls.
Serum testosterone levels: The serum testosterone levels of men with IED were
mean + SEM 21.8 + 1.65 nmol/L and the serum testosterone levels of men without
IED were 16.4 + 2.10 nmol/L. There was a tendency towards higher age-adjusted
serum testosterone levels in men with IED compared with subjects without this diag-
nosis, although the difference was not statistically significant (mean + SEM 21.3 +
0.51 nmol/L vs.17.4 + 1.05 nmol/L; F (1,13) = 1.567, p = 0.08).
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Table 5. The polysomnography parameters.
A = antisocial personality disorder, B = antisocial and borderline personality disorders CDs = conduct
disorder type severe, CDm = conduct disorder type mild or moderate, IED+ = intermittent explosive
disorder, IED- = no intermittent explosive disorder, CO = controls, TST = total sleep time, AST =
actual sleep time, SE = sleep efficiency,  S1-S4 = sleep stages 1–4, SWS = slow wave sleep, REM =
rapid eye movement sleep, lat = latency, NS = difference is not statistically significant. Comparisons
made using one-way ANOVA with post-hoc Student-Newman-Keul’s method (normally distributed
values) and Kruskal- Wallis ANOVA on ranks with post-hoc Dunn‘s method (non-normally distrib-
uted values). * = one-way analysis of covariance with age as an independent factor. All values
expressed as mean + SEM.
A B CO statistics
n = 10 n = 6 n = 11
Polysomnography
TST (min) 429.7 + 24.37 500.3 + 35.29 461.8 + 21.47 F = 1.606, P = NS
AST (min) 396.9 + 18.66 455.3 + 28.09 442.6 + 22.61 F = 1.778, P = NS
SE (%) 95.3 + 0.86 89.3 + 2.85 95.7 + 1.51 F = 3.890, P = 0.03
A vs. B q = 3.400, P = 0.02
B vs. CO q = 3.705, P = 0.04
sleep lat (min) 21.4 + 8.21 17.9 + 5.40 18.5 + 7.00 H = 0.877, P = NS
awakenings (n) 10.7 + 1.65 24.7 + 4.53 11.7 + 1.26 F = 9.815, P< 0.001
A vs. B q = 5.823, P= 0.001
B vs. CO q = 5.489, P< 0.001
S1 (min) 23.6 + 5.79 26.9 + 2.12 23.3 + 5.38 H = 2.878, P = NS
S1 (%) 6.7 + 1.39 6.0 + 0.64 5.3 + 1.15 H = 1.610, P = NS
S2 (min) 176.8 + 12.53 226.3 + 26.54 228.7 + 11.91 F = 3.873, P = 0.04
A vs. CO q = 3.648, p = 0.042
A vs. B q = 2.942, p = 0.048
S2 (%) 44.3 + 1.83 49.0 + 3.44 51.7 + 1.33 F = 4.194, P = 0.03
A vs. CO q = 4.077, P 0.02
S3 (min) 38.5 + 3.66 36.6 + 5.78 63.5 + 5.74 F = 8.916, P = 0.001
A vs. CO, q = 5.200, P = 0.001
B vs. CO, q = 4.810, P = 0.006
S3 (%) 9.9 + 1.17 7.7 + 0.89 14.6 + 1.40 F = 7.144, P = 0.004
A vs. CO q = 3.899, P = 0.01
B vs. CO q = 4.934, P = 0.005
S4 (min) 68.2 + 10.34 63.8 + 11.21 24.9 + 4.29 F = 8.856, P = 0.001
A vs. CO q = 5.528, P = 0.002
B vs. CO q = 4.279, P = 0.006
S4 (%) 17.2 + 2.48 14.4 + 2.63 6.3 + 0.96 F = 9.107, P = 0.001*
A vs. CO q = 3.960, P < 0.001
B vs. CO q = 2.997, P = 0.006
SWS (min) 104.8 + 9.93 100.3 + 11.99 88.4 + 7.56 F = 0.914, P = NS
SWS (%) 27.1 + 2.38 22.1 + 2.32 21.0 + 1.31 F = 2.209, P = NS*
REM lat (min) 111.9 + 8.25 83.2 + 10.84 105.3 + 16.75 F = 0.951, P = NS
REM (min) 86.2 + 6.10 101.7 + 6.70 98.4 + 9.69 F = 0.934, P = NS
REM (%) 21.7 + 1.18 22.7 + 2.05 21.8 + 1.32 F = 0.128, P = NS
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CDs CDm CO statistics
n= 8 n= 8 n=11
Polysomnography
TST (min) 425.4 + 25.90 478.0 + 28.33 461.8 + 21.47 F = 1.055, P = NS
AST (min) 402.9 + 24.1 434.6 + 23.57 442.6 + 22.61 F = 0.773, P = NS
SE (%) 94.8 + 1.38 91.3 + 2.28 95.7 + 1.51 H = 5.765, P = NS
sleep lat (min) 26.1 + 9.67 30.9 + 16.57 18.5 + 7.00 F = 0.346, P = NS
awakenings (n) 14.5 + 2.87 21.6 + 4.01 11.7 + 1.26 F = 3.630, P = 0.04
CDm vs. CO q = 3.765, P = 0.04
S1 (min) 17.9 + 3.21 31.9 + 5.71 23.3 + 5.38 F = 1.720, P = NS
S1 (%) 5.6 + 1.07 7.4 + 1.40 5.3 + 1.15 F = 0.843, P = NS
S2 (min) 157.1 + 24.65 218.8 + 21.35 228.7 + 11.91 F = 4.154, P = 0.03
CDs vs. CDm q = 3.115, P = 0.04
CDs vs. CO q = 0.029, P = 0.03
S2 (%) 42.6 + 1.91 49.5 + 2.47 51.7 + 1.33 F = 6.596, P = 0.005
CDs vs. CDm q = 3.528, P = 0.02
CDs vs. CO q = 5.045, P = 0.004
S3 (min) 36.4 + 5.24 39.1 + 3.41 63.5 + 5.75 F = 8.968, P = 0.001
CDs vs. CO q = 5.289, P = 0.003
CD m vs. CO q = 4.776, P = 0.003
S3 (%) 9.2 + 1.55 9.0 + 0.74 14.6 + 1.40 F = 6.238, P = 0.007
CDs vs. CO q = 4.138, P = 0.008
CDm vs. CO q = 4.281, P = 0.02
S4 (min) 83.4 + 9.18 49.7 + 8.66 24.9 + 4.29 F = 17.409, P < 0.001
CDs vs. CDm q = 4.472, P = 0.004
CDs vs. CO q = 8.345, P < 0.001
CDm vs. CO q = 3.533, P = 0.02
S4 (%) 20.6 + 1.91 11.6 + 2.19 6.3 + 0.96 F = 19.167, P<0.001*
CDs vs. CDm q = 3.394, P = 0.002
CDs vs. CO q = 6.191, P< 0.001
CDm vs. CO q = 2.567, P = 0.02
SWS (min) 119.9 + 9.88 88.6 + 7.75 88.46 + 7.56 F = 4.397, P = 0.02
CDs vs. CDm q = 3.524, P = 0.02
CDs vs. CO q = 3.813, P = 0.03
SWS (%) 29.8 + 1.93 20.6 + 2.00 21.0 + 1.31 F = 8.250, P = 0.002*
CDs vs. CDm q = 3.455, P = 0.002
CDs vs. CO q = 3.696, P = 0.001
REM lat (min) 125.7 + 18.77 72.4 + 11.43 105.3 + 16.75 F = 2.404, P = NS
REM (min) 88.3 + 7.13 95.6 + 6.74 98.4 + 9.69 F = 0.367, P = NS
REM (%) 21.9 + 1.28 22.3 + 1.72 21.8 + 1.32 F = 0.034, P = NS
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IED+ IED- CO statistics
n= 10 n= 5 n= 11
polysomnography
TST (min) 455.3 + 21.78 458.5 + 47.77 461.8 + 21.47 F = 0.018, P = NS
AST (min) 428.7 + 21.41 409.2 + 33.55 442.6 + 22.61 F = 0.376, P = NS
SE (%) 94.0 + 1.01 90.5 + 3.87 95.7 + 1.51 H = 4.084, P = NS
sleep lat (min) 33.1 + 13.59 11.0 + 5.32 18.5 + 7.00 H = 3.109, P = NS
awakenings (n) 17.8 + 1.84 21.0 + 7.31 11.7 + 1.26 H = 4.752, P = NS
S1 (min) 21.1 + 2.49 36.2 + 8.59 23.3 + 5.38 F = 1.779, P = NS
S1 (%) 5.8 + 0.74 8.8 + 2.03 5.3 + 1.15 H = 4.479, P = NS
S2 (min) 195.9 + 18.47 172.5 + 45.94 228.7 + 11.91 F = 1.595, P = NS
S2 (%) 45.0 + 2.50 47.2 + 2.66 51.7 + 1.33 F = 3.159, P = NS
S3 (min) 36.3 + 3.95 42.0 + 5.74 63.5 + 5.75 F = 8.445, P = 0.002
IED+ vs. CO q = 5.605, P = 0.002
IED- vs. CO q = 0.019, P = 0.02
S3 (%) 8.3 + 0.75 10.7 + 2.19 14.6 + 1.40 F = 6.658, P = 0.005
IED+ vs. CO q = 5.122, P = 0.004
S4 (min) 79.4 + 8.50 38.8 + 8.26 24.9 + 4.29 F = 18.784, P < 0.001
IED+ vs. IED- q = 5.057, P = 0.002
IED+ vs. CO q = 8.509, P < 0.001
S4 (%) 18.9 + 2.07 9.6 + 2.22 6.3 + 0.96 F = 15.131, P< 0.001*
IED+ vs. IED- q = 2.822, P = 0.01
IED+ vs. CO q = 5.484, P< 0.001
SWS (min) 115.7 + 8.95 80.6 + 8.37 88.4 + 7.56 F = 4.345, P = 0.03
IED+ vs. IED- q = 3.555, P = 0.05
IED+ vs. CO q = 3.464, P = 0.02
SWS (%) 27.2 + 2.02 20.4 + 3.36 21.0 + 1.31 F = 2.653, P = NS*
REM lat (min) 86.6 + 9.53 126.8 + 35.08 105.3 + 16.75 F = 1.006, P = NS
REM (min) 92.0 + 4.52 96.6 + 12.46 98.4 + 9.69 F = 0.165, P = NS
REM (%) 21.7 + 1.54 23.4 + 2.39 21.8 + 1.32 F = 0.317, P = NS
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Table 6.  The percentual spectral power in relation to the total power in stages 2+3+4. A = antisocial
personality disorder, B = antisocial and borderline personality disorders, CDs = conduct disorder type
severe, CDm = conduct disorder type mild or moderate, IED+ = intermittent explosive disorder, IED-
= no intermittent explosive disorder, CO = controls, NS = difference is not statistically significant.
Comparisons made using one-way ANOVA with post-hoc Student- Newman-Keul’s method (all
values normally distributed )  * = one-way analysis of covariance with age as an independent factor. All
values expressed as mean + SEM.
A B CO statistics
 n = 10 n = 6 n = 11
first half of the night
theta power (%)
stage 4 13.6 + 1.17 10.8 + 2.55 5.0 + 0.93 F = 11.546, P < 0.001
A vs. CO q = 6.679, P < 0.001
B vs. CO q = 3.883, P = 0.01
stage 3+4 17.4 + 0.81 14.8 + 2.47 13.9 + 0.88 F = 2.442, P = NS
delta power (%)
stage 4 20.9 + 5.03 12.4 + 3.25 4.9 + 1.17 F = 5.907, P = 0.008
A vs. CO q = 4.861, P = 0.006
stage 3+4 24.2 + 5.13  15.6 + 3.21 10.9 + 1.52 F = 3.850, P = 0.04
A vs. CO q = 3.900, P = 0.03
the whole night
theta power (%)
stage 4 11.7 + 1.16 7.7 + 1.66 3.8 + 0.63 F = 15.267, P < 0.001*
A vs. CO q = 5.490, P < 0.001
B vs. CO q = 2.696, P = 0.01
stage 3+4 15.4 + 0.88 11.3 + 1.58 11.3 + 0.95 F = 4.194, P = 0.03*
A vs. CO q = 2.739, P = 0.01
delta power (%)
stage 4     17.7 + 4.73     9.0 + 2.41 3.5 + 0.80 F = 8.938, P = 0.001*
A vs. CO q = 4.082, P < 0.001
B vs. CO q = 2.594, P = 0.02
stage 3+4 21.2 + 4.88 12.1 + 2.51 8.3 + 1.11 F = 5.040, P = 0.02*
A vs. CO q = 3.154, P = 0.004
CDs CDm CO statistics
n = 8 n = 8 n = 11
first half of the night
theta power (%)
stage 4 15.5 + 1.14 9.6 + 1.56 5.0 + 0.93 F = 20.152, P < 0.001
CDs vs. CDm q = 4.706, P = 0.003
CDs vs. CO q = 8.977, P < 0.001
CDm vs. CO q = 3.913, P = 0.01
stage 3+4 18.8 + 0.97 14.0 + 1.48 13.9 + 0.88 F = 6.202, P = 0.007
CDs vs. CDm q = 4.142, P = 0.007
CDs vs. CO q = 4.560, P = 0.01
delta power (%)
stage 4 25.9 + 5.44 9.6 + 1.60 4.9 + 1.17 F = 13.140, P < 0.001
CDs vs. CDm q = 5.112, P = 0.002
CDs vs. CO q = 7.084, P < 0.001
stage 3+4 28.9 + 5.67 13.0 + 1.55 10.9 + 1.52 F = 9.244, P = 0.001
CDs vs. CDm q = 4.728, P = 0.003
CDs vs. CO q = 5.767, P = 0.001
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the whole night
theta power (%)
stage 4 12.9 + 1.26 7.5 + 0.99 3.8 + 0.63 F = 24.204, P < 0.001*
CDs vs. CDm q = 3.616, P = 0.002
CDs vs. CO q = 6.951, P < 0.001
CDm vs. CO q = 3.096, P = 0.005
stage 3+4 16.0 + 1.0 11.8 + 1.17 11.3 + 0.95 F = 4.734, P = 0.02*
CDs vs. CDm q = 2.323, P = 0.03
CDs vs. CO q = 2.968, P = 0.007
delta power (%)
stage 4 21.5 + 5.36 7.4 + 1.05 3.5 + 0.80 F = 11.230, P < 0.001*
CDs vs. CDm q = 3.986, P = 0.002
CDs vs. CO q = 4.662, P < 0.001
CDm vs. CO q = 2.674, P = 0.01
stage 3+4 24.7 + 5.62 10.8 + 1.28     8.3 + 1.11 F = 7.762, P = 0.003*
CDs vs. CDm q = 2.306, P = 0.03
CDs vs. CO q = 3.938, P < 0.001
IED+ IED- CO statistics
n = 10 n = 5 n = 11
first half of the night
theta power (%)
stage 4 14.4 + 1.46 9.0 + 1.66 5.0 + 0.93 F = 15.745, P < 0.001
IED+ vs. IED- q = 3.688, P = 0.02
IED+ vs. CO q = 7.925, P < 0.001
stage 3+4 18.1 + 1.14 13.4 + 1.90 13.9 + 0.88 F = 4.981, P = 0.02
IED+ vs. IED- q = 3.499, P = 0.05
IED+ vs. CO q = 3.980, P = 0.01
delta power (%)
stage 4 18.1 + 3.39 9.6 + 2.92 4.9 + 1.17 F = 7.879, P = 0.002
IED+ vs. IED- q = 2.857, P 0.05
IED+ vs. CO q = 5.584, P = 0.002
stage 3+4 21.0 + 3.16 13.1 + 3.28 10.9 + 1.52 F = 4.731, P = 0.02
IED+ vs. CO q = 4.246, P = 0.02
the whole night
theta power (%)
stage 4 11.3 + 1.42 7.9 + 1.42 3.8 + 0.63 F = 12.700, P < 0.001*
IED+ vs. IED- q = 2.462, P = 0.04
IED+ vs. CO q = 4.944, P < 0.001
IED- vs. CO q = 2.628, P = 0.02
stage 3+4 14.8 + 1.16 12.5 + 1.80 11.3 + 0.95 F = 2.107, P = NS*
delta power (%)
stage 4 14.3 + 3.49 8.2 + 2.23 3.5 + 0.80 F = 7.890, P = 0.003*
IED+ vs. IED- q = 3.012, P = 0.02
IED+ vs. CO q = 3.803, P = 0.001
IED- vs. CO q = 2.393, P = 0.03
stage 3+4 17.2 + 3.48 12.0 + 2.95 8.3 + 1.11 F = 4.008, P = 0.03*
IED+ vs. CO q = 2.751, P = 0.01
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Figure 4. Results for polysomnography and spectral power analysis during the whole night in differ-
ent subgroups of antisocial violent offenders (CDs = 8 males with preceding type severe conduct
disorder, CDm = 8 males with preceding type mild or moderate conduct disorder, IED+ = 10 males
with intermittent explosive disorder, IED- = 5 males with no intermittent explosive disorder) and 11
controls (CO). Comparisons were made using one- way ANOVA with post- hoc Student-Newman-
Keul´s method (all values normally distributed). S4 = sleep stage 4, ST = stage.
* = p < 0.05, ** = p < 0.01, *** = p < 0.001
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IV. Effect of a single-dose of olanzapine on sleep in healthy females and males
General conditions: The study comprised seven men and six women (age 25.3 years
+ 2.1 vs. 33.2 years + 3.0; t (12) = –2.214, p = 0.05). Neither the body weights (70.8
kg  + 5.8 in females vs. 77.9 kg  + 2.0 in males; t (12)= 1.2, p = NS) nor the body
mass indexes  (BMI) (25.1 + 1.8 in females vs. 24.9 + 0.8 in males; t (12) = 0.09, p
= NS) differed significantly between the sexes.
PSG: The number and structure of sleep cycles did not change after olanzapine
administration. The decline in delta power both within an individual sleep bout and
during successive sleep bouts across the night remained normal. After olanzapine
administration, the sleep bouts appeared to be more consolidated (Figure 5.). For
details of the PSG, see Table 7. and Figure 6. Sleep latency, AST and SWS (both
actual and percentage amount) was higher in both sexes, but the increases were only
statistically significant in women. The same phenomenon was observed in REM la-
tency and in total duration of REM sleep in minutes. The percentage amount of REM
sleep decreased in both sexes, but the change was only significant in women.
SPA:  Olanzapine slightly increased the relative delta power in stages 2 + 3+ 4 during
the first four hours of sleep in both sexes, but the changes were not statistically
significant (all 16.486  + 2.193 vs. 17.788 + 1.876; t (12) = –1.371, p= NS, men
16.657 + 2.431 vs. 17.192 + 2.130; t (6) = -0.461, p = NS, women 16.286 + 4.089
vs. 18.483 + 3.431; t (5) = -1.388, p = NS). The relative theta power in stages
2+3+4, on the other hand, increased significantly in both sexes (all 28.818 + 1.650
vs. 33.223 + 1.713; t (12) = -3.834, p = 0.002, men 29.467 + 2.338 vs. 32.812 +
2.382; t (6) = -3.477, p = 0.01, women 28.062 + 2.509 vs. 33.703 + 2.690; t (5) = –
2.523, p = 0.05) (Figure 6.).
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Table 7. Results for polysomnography in 13 healthy subjects (7men and 6 women) before and
after administration of 10 mg olanzapine. Comparisons were made using paired t-test (normally
distributed values) or Wilcoxon signed rank test (non-normally distributed values). SE = sleep effi-
ciency, AST = actual sleep time, S1-S4 = sleep stages 1–4, SWS = slow wave sleep, REM = rapid eye
movement sleep, NS = change is not statistically significant, NP = non-normally distributed values. All
values expressed as mean + SEM.
ALL before after t (df=12) p
sleep latency (min) 316.8+12.5 224.4+ 24.3 3.462 0.005
SE (%) 6.6+ 1.0 97.3+ 1.1 –0.783 NS
AST (min) 461.2 + 23.6 585.8 +41.7 –3.789 0.003
awakenings (n) 14.3 + 1.7 13.3 + 3.1 0.491 NS
S1  (min) 24.5 + 5.8 16.5 + 3.7 –1.539 NS/NP
S1  (%) 5.1 + 1.4 2.9 + 0.7 2.112 NS
S2  (min) 238.1 + 13.9 296.9 + 24.7 –3.383 0.005
S2  (%) 51.3 + 1.3 50.1 + 1.3 2.236 0.04
S3  (min) 66.3 + 4.4 101.5 + 7.2 –4.036 0.002
S3  (%) 14.6 + 1.0 17.6 + 0.8 –2.969 0.01
S4  (min) 30.2 + 5.1 46.7 + 8.3 –2.393 0.03
S4  (%) 6.1 + 0.9 7.6 + 1.1 –1.585 NS
SWS (min) 96.5 + 6.2 148.2 + 10.9 –5.128 < 0.001
SWS (%) 20.8 + 0.7 25.4 + 0.7 –5.393 < 0.001
REM latency (min) 94.4 + 13.8 108.7 + 13.4 –0.767 NS
REM  (min) 107.6 + 9.8 124.2 + 9.9 –2.162 0.05
REM  (%) 22.7 + 1.2 21.4 + 1.1 1.445 NS
MEN before after t (df=6) p
sleep latency (min) 311.0+ 20.8 247.2+ 34.1 1.814 NS
SE (%) 94.8+ 1.2 98.3+ 0.5 –1.156 NS
AST (min) 450.8 + 27.8 518.0 + 60.8 –1.313 NS
awakenings 13.0 + 1.7 11.4 + 2.0 0.755 NS
S1  (min) 28.3 + 8.4 15.4 + 3.1 1.380 NS
S1  (%) 5.4 + 2.0 2.9 + 1.2 1.430 NS
S2  (min) 224.8 + 14.2 251.0 + 34.7 –1.032 NS
S2  (%) 49.9 + 1.6 48.0 + 1.7 –3.736 0.01
S3  (min) 70.2 + 5.5 95.8 + 9.4 –2.304 NS
S3  (%) 15.8 + 1.4 18.8 + 0.8 2.269 NS
S4  (min) 29.6 + 7.6 37.5 + 6.3 –1.021 NS
S4  (%) 6.2 + 1.5 7.1 + 0.7 0.590 NS
SWS (min) 99.8 + 7.8 133.3 + 14.6 –2.222 NS
SWS (%) 20.5 + 0.8 25.6 + 1.0 2.695 NS/NP
REM latency (min) 99.7 + 25.0 103.5 + 21.8 –0.110 NS
REM  (min) 106.4 + 13.1 117.4 + 13.5 0.853 NS
REM  (%) 23.1 + 1.7 22.9 + 1.5 –0.146 NS
WOMEN before after t (df=5) p
sleep latency (min) 23.5+ 13.9 201.7+ 35.0 3.043 0.03
SE (%) 96.4+ 1.7 96.0+ 2.3 0.527 NS
AST (min) 473.4 + 42.0 664.9 + 39.1 –11.287 <0.001
awakenings 15.8 + 3.6 15.5 + 6.4 0.085 NS
S1  (min) 20.0 + 8.4 17.7 + 7.6 0.987 NS
S1  (%) 4.6 + 2.3 3.0 + 1.5 1.887 NS
S2  (min) 253.7 + 25.2 349.5 + 21.3 –9.569 <0.001
S2  (%) 52.9 + 2.1 52.6 + 1.5 0.403 NS
S3  (min) 61.8 + 7.0 108.0 + 11.3 –3.493 0.02
S3  (%) 13.2 + 1.3 16.2 + 1.4 –1.779 N
S4  (min) 31.0 + 7.4 57.5 + 16.3 –2.365 NS
S4  (%) 6.0 + 1.1 8.4 + 2.3 –1.461 NS
SWS (min) 92.8 + 10.5 165.5 + 14.3 –11.129 <0.001
SWS (%) 19.1 + 0.8 24.7 + 1.0 –6.780 0.001
REM latency (min) 88.2 + 9.9 114.8 + 16.1 –2.945 0.03
REM  (min) 109.1 + 16.1 132.2 + 15.2 –3.054 0.03
REM  (%) 22.3 + 1.9 19.6 + 1.6 2.835 0.04
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5.  DISCUSSION
5.1.  Methodological aspects
5.1.1.  General
As a research method, PSG is a time-consuming procedure, which is fairly burden-
some for a subject and for a researcher. It demands good collaboration between the
two and is dependent on the subject‘s ability to follow the instructions. In addition,
visual scoring of the sleep recording takes time and requires special expertise. These
reasons at least partly explain the relatively small sample size, which is typically seen
in PSG studies. This limitation is also seen in this work.
Figure 5. Delta power in sleep recordings before and after administration of 10 mg olanzapine.
Recording from a) a man and b) a woman. The cyclic structure of sleep is unaffected by olanzapine. The
duration of sleep increased in the recording of the woman but not in the recording of the man after
olanzapine. In the man, a slight increase in delta power is seen during the second sleep cycle while, in
the woman, delta power appears to be increased in all four sleep cycles. One epoch is 30 s.
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Figure 6. Results for polysomnography and spectral power analysis in seven men and six women
before and after administration of 10 mg olanzapine. Comparisons were made using paired t-test
(normally distributed values) or Wilcoxon signed rank test (non-normally distributed values). SWS =
slow wave sleep, ST = stage.
* = p < 0.05, ** = p < 0.01, *** = p < 0.001
5.1.2.  Sleep assessment
5.1.2.1.  Diagnostic process
The important detail, which significantly affects the results of PSG studies is the
comorbidity that is often seen among psychiatric patients. The ability to avoid or at
least be aware of this confounding factor is based on a reliable diagnostic process
which takes account of both axis I and axis II diagnoses.
One of the most common phenomena to take into account is the comorbidity of
depression and the degree of it. Changes in sleep architecture have been documented
most extensively in patients with major depression. In contrast, dysthymic patients
tended to display sleep patterns similar to those of normal controls (Benca, 2000). In
52
Sleep in mental and behavioural disorders
a study by Cohen (1979), significant sleep disturbances were not seen in depressed
patients who did not meet the criteria for major depression, and in individuals with
depressed mood but not with mood disorder.
The inevitable consequence of the strict exclusion criteria, which aim to produce
diagnostically “pure” study groups, is that the number of subjects often remains
small, the findings must be regarded as indicative, and the conclusions must be drawn
with care.
In AN in particular, PSG studies have yielded conflicting results (Levy et al., 1988).
This is most probably due to the heterogeneous patient material, with variations in
the degree of comorbidity between, and sometimes also within, the studies. We se-
lected the patients with care in order ensure that they represented a uniform sub-
group, so as to be able more accurately to describe the changes in the sleep. In the
present study (I), the entire study group had the same subtype of AN and the degree
of depression was only mild, and was probably secondary to the starvation state
(Halmi, 2000).
All ASPs (II and III) were evaluated as highly aggressive with major psychological
and social problems, but, they were nonetheless responsible for the violent acts they
were being charged with. The opportunity to exclude ASPs with psychiatric disor-
ders known to affect sleep architecture helped us to create a homogeneous group of
habitually violent offenders with axis II diagnosis as the primary clinical diagnosis.
As far as ASP is concerned, with prevalence rates of three percent for males in the
general population (Cloninger and Svrakic, 2000), the study group represents an
extreme subgroup even for a criminal population. For this reason, the results cannot
be generalized to apply to the whole diagnosis group. Even among ASPs, the degree
of depression was mild.
5.1.2.2.  Placement of electrodes
In non-REM sleep the highest amplitude of theta power is in the posterior region
(Werth et al., 1997) and this was the reason for choosing the O2-P4 derivation to
maximize the detection of changes in theta power. As compared with the traditional
Rechtschaffen-Kales (R-K) derivation (100%), the chosen derivation overestimates
the detection of theta power (118%) and underestimates the detection of delta power
(93 %). This suggests that using the R-K derivation the increase in theta power might
have been slightly smaller and on contrary the increase in delta power even larger.
The theta power was significantly higher in controls compared with anorectics and in
anorectics after weight gain compared with anorectics before weight gain. The same
kind of tendency was seen in delta power (I). Olanzapine significantly increased theta
power in both sexes and, the same kind of tendency was seen for delta power (IV).  It
is possible to speculate that, if the R-K derivation had been used, the changes seen in
delta power would have become statistically significant. Among ASPs, both  delta
and theta power were significantly higher compared with controls (II). Using the R-
K derivation, the difference in delta power between ASPs and controls would have
been even more significant.
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However, both theta and delta power decline during the night and increase with the
duration of wakefulness preceding sleep as markers of a homeostatic sleep process
(Borbély et al., 1981), even if this homeostatic process has traditionally been defined
through delta power. In fact, it seems that theta power acts as a sensitive indicator of
sleep and sleep changes.
5.1.2.3.  Registration environment
The results suggest that PSG monitoring in the patient’s home is more sensitive than
PSG in a sleep laboratory when it comes to documenting specific alterations in sleep
(Hajak, 2000).  The sleep recordings among healthy volunteers were made in a guest
room of the psychiatric hospital (I–IV). The room was quiet and looked more like a
bedroom than a sleep laboratory. On the other hand, spending the night in a mental
hospital could have slightly worsened their quality of sleep. The situation was quite
the opposite among ASPs (II–III). The structured daily activities and demand for
silence during the night could have improved their sleep, opposite to that outside the
hospital, suggesting that the present studies may underestimate the degree of sleep
disturbances in their ordinary lives. However, the unstructured lifestyle of these
males, with severe drug and alcohol dependence combined with abusive behaviour,
would make a PSG study almost impossible to perform outside the hospital or the
prison.
The first-night effect is a well-known phenomenon in sleep recordings and it is
mainly characterized by lower SE, longer S2 and REM latencies, as well as a lower
percentage amount of REM sleep. The effect has been shown to be more pronounced
in healthy subjects than in psychiatric in-patients (Toussaint et al., 1995). It has
become a common practice to exclude the first night of sleep from the analysis, and
this was also done in our studies.
5.1.2.4.  Age
It is well known that age affects the sleep architecture. The most easily recognized
age-related change is the reduction in SWS observed by the age of approximately 20
(Bliwise, 1993). There is some disagreement about whether REM time or REM la-
tency varies with ageing (Bliwise, 2000). In a study by Landolt et al. (1996), the
effect of age on sleep was investigated in healthy older men (62.0 years) and young
men (22.4 years) taking no medication. TST, SE and SWS were lower in older men,
while S1 and wakefulness after sleep onset were higher. In this study, no changes in
REM parameters, including REM latency, were seen between the groups. In older
men, EEG power density in non-REM sleep was reduced at frequencies below 14.0
Hz, whereas related reductions in REM sleep were limited to the delta-theta (0.25–
7.0 Hz) and low alpha (8.25–10.0 Hz) band.
AN has a bimodal peak of onset either between the ages of 14 and 15, or at the age of
18 (Halmi, 2000). One of the conflicting effects in sleep studies among anorectics is
that these two different age groups are not always studied separately. In this work (I),
the whole AN group consisted of the older subjects in order to create a homogeneous
study group as well as it was possible.
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The effect of age on sleep underlines the importance of matching when different
study groups are compared. In our studies (I–III) no significant differences were seen
between subjects and controls from this point of view. In Study IV, women were
slightly older than men. However, both sexes slept equally well during the adaptation
and placebo nights. As a result, the age difference, which was in fact fairly minimal,
can hardly be seen as an explanation of the results.
5.1.2.5.  Sex
In a study by Dijk et al. (1989) young adult age-matched men and women did not
display any differences in the amount of SWS or REM sleep. SPA, however, detected
significantly higher power densities during both non-REM and REM sleep over a
wide frequency range (0.25–11.0 Hz) in the female subjects as compared with the
male ones. The authors speculated that the changes might be caused by sex differ-
ences in skull characteristics, for example by the shape and bone thickness of the
skull . In a study by Ehlers and Kupfer (1997), men and women in their twenties
were also found to have similar percentages of SWS and mean EEG slow-wave
activity. However, significant reductions in the percentage of SWS and mean slow-
wave activity during the night occurred in men during their thirties but not in
women. The findings suggest that the sleep in of men and women above age 20–40
may develop differently. So, although the effect of sex on sleep architecture is not
dramatic, it should be taken into account when different study groups are compared.
In our work (I–III), all the controls were sex-matched.
5.1.2.6.  Weight
As sleep parameters as well as hormone secretion patterns are affected by weight
(Benca and Casper, 2000; Veldhuis and Iranmanesh, 1996; Garnier et al., 1990) we
selected the subjects with care in order to ensure that they represent a uniform group
so as to be able more accurately to describe the changes in sleep and hormone levels.
In study I, the starvation state was very serious at admission. The patients remained
underweight even after the treatment period in hospital. In studies II and III the mean
BMIs of the ASPs and controls did not significantly differ. However, the ASPs had
stayed approximately 4 months in institutions with regular meals and limited physi-
cal exercise. One can assume that this kind of lifestyle is quite different compared
with the one they are used to. This might have caused mild weight gain before the
sleep examinations. Lacey et al. (1978) examined the immediate influence of intra-
venous amino acids and glucose on sleep as measured by PSG recordings in healthy
women within a normal weight range. Both solutions increased SWS, while TST was
not affected. The study indicates that body weight has a direct correlation to SWS.
However, the changes reported by Lacey et al. were fairly minimal and hardly can be
seen as an explanation of the significantly high amount of S4 sleep in ASPs. Willi et
al. (1998) reported abnormally high SWS levels in adolescents with morbid obesity
(mean BMI 50.9 kg/m2), which tended to normalise with weight loss (mean BMI 5.4
kg/m2). The authors attributed this change to significant amelioration of obstructive
sleep apnea syndrome, the phenomenon not present in ASPs. In study IV the mean
BMIs of women and men did not significantly differ.
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5.1.2.7.  Medication
Numerous prescription drugs for the treatment of both somatic and psychiatric disor-
ders act within the central nervous system (CNS) and have the potential to affect
sleep. Insomnia, sleepiness, sedation, and fatigue are common side-effects of many
medicines. Sleep itself, as well as drug pharmacokinetics, is influenced by age and
sex; it is therefore difficult to generalize on the basis of studies that are often con-
ducted on young healthy male individuals. Moreover, healthy individuals may re-
spond differently from the population for whom the treatment is intended. Many
patients take a variety of drugs in combination, which may affect one another. Little
research has been conducted on drug combinations (Schweitzer, 2000).  To avoid
these heterogeneous effects associated with medication, healthy volunteers and
anorectics and ASPs were totally drug free during the entire registration period and
two weeks prior to the first sleep registration. During the recording process, one of
the volunteers was prescribed an sedative analgesic (tramadol hydrochloride) for a
transient headache by his doctor and was excluded from the study (IV). The
anorectics for whom medication was started in order to facilitate the healing process
were also excluded from the sleep examinations made after the weight gain (I).
5.1.2.8.  Alcohol and illicit drugs
As described earlier (1.7. Alcohol and sleep) alcohol affects sleep significantly both
in dependence syndrome and in the withdrawal state. ASP is frequently combined
with substance abuse (Robins, 1998). In Study III, 16 of 19 ASP offenders were also
alcoholics, representing Cloninger early-onset type 2 alcoholism. However, the ASPs
had spent over four months in prisons or hospital with no alcohol intake. Therefore it
seems improbable that their sleep would have been affected by alcohol withdrawal
syndrome. In the light of previous PSG studies of type 1 alcoholism, it is also im-
probable that the results, with large amounts of SWS and S4, could be explained by
comorbidity with alcoholism.
Relatively few studies have investigated sleep patterns during illegal drug use or after
withdrawal from drug dependence. Amphetamine and other stimulants have been
reported to prolong sleep latency and reduce TST. They also affect REM parameters,
resulting in increased REM latency and reduced REM % (Gillin and Drummond,
2000). The sleep abnormalities related to stimulant withdrawal include reduced SE,
increased nocturnal wake time, increased S1 and REM sleep, and shorter REM la-
tency. These sleep abnormalities remained for at least the first two weeks of absti-
nence (Watson et al., 1972). The short-term administration of opiates to normal
controls or abstinent addicts reduced SE, TSL, SWS and REM sleep (Kay et al.,
1981). With chronic administration, the REM-suppressing effects of morphine were
lost within a week (Staedt, 1996). In a study by Feinberg et al. (1976), the effects of
delta-9-tetrahydrocannabinol (TCH) in PSGs were studied in four experienced male
marijuana users. The S4 sleep tended to increase with drug administration. An abrupt
withdrawal led to an increase in REM sleep, and a sharp fall in S4 to baseline levels
was seen. Many of the ASPs (II–III) were also dependent on drugs. The drugs that
were primary used were cannabis and amphetamine. In fact, in this study group,
there were no individuals with opiate dependence. The occasional use of illicit drugs
during imprisonment is, unfortunately, not completely excluded, but the urine
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screenings for illicit drugs were made just before the sleep examinations and they
were negative in all cases. The approximate duration of the detectability of cannabis
is approximately 10 days in the case of recreational users and three to four weeks in
the case of heavy users (Gillin and Drummond, 2000). So, it is unlikely that the
results, especially the increase in S4, could be explained by the abuse of cannabis.
5.1.2.9.  Caffeine
Caffeine and other methylxanthines are stimulants that are found not only in coffee but
also in tea, cola and cocoa. A normal cup of brewed coffee contains about 100 to 150
mg of caffeine.  Individuals differ in their response to caffeine, some people being
over-stimulated by as little as 250 mg (Gillin and Drummond, 2000). Although the
half-life of caffeine is about three to seven hours, the effects may last for as long as
eight to 14 hours (James, 1998). Caffeine clearance in chronic hepatitis patients has
been reported to be significantly lower than in normal subjects (Wittayalertpanya et al.,
1996). So, caffeine may have significant effects on sleep at night, even if it is con-
sumed in the afternoon or early evening. From the perspective of sleep-wake regula-
tion, caffeine appears to promote wakefulness by blocking adenosine receptors in the
brain (Gillin and Drummond, 2000). Many people, however, develop tolerance, and
apparently sleep well, according to subjective reports (Gillin and Drummond, 2000).
The Finns consume large quantities of coffee, and especially among psychiatric in-
patients coffee drinking is very important as a social habit. To promote compliance, the
participants were allowed to consume their normal amount of caffeine.
5.1.2.10.  Nicotine
Nicotine dependence is about two to three times higher in patients with mental disor-
ders than in normal population. The plasma half-life of nicotine is about 2 hours and
for the average smoker, who smokes throughout the day, plasma concentration of
nicotine increases over the course of the day and falls throughout the night, although
it remains detectable in the morning (Gillin and Drummond, 2000). Both PSG and
questionnaire studies have reported increased sleep latency as well as difficulty to
stay asleep at night in active smokers compared with non-smokers (Davila et al.,
1994). Acute nicotine withdrawal has been reported to increase arousals and number
of awakenings during night (Wetter et al., 1995). Nicotine replacement therapy has
been shown to decrease this sleep fragmentation and increase the amount of SWS as
a recovery effect after sleep deprivation associated with the withdrawal state (Wetter
et al., 1995). To promote compliance, the participants were allowed to smoke their
normal amount of cigarettes. Opposite to other subjects and controls, most of the
ASPs were heavy smokers with approximately 20 cigarettes a day. However, in the
light of previous PSG studies of tobacco smoking, it is improbable that the results,
with large amounts of SWS and S4, could be explained by nicotine dependence.
5.1.2.11.  Brain traumas
Brain contusions produce gliotic scars or focal atrophy as long-term sequelae. These
focal abnormalities most probably affect the patient’s sleep architecture, although no
PSG follow-up studies in this field are available. A brain MRI (1.5T) was performed
on both subjects and controls (II-IV) and no post-traumatic signs in the brain sub-
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stance were reported. Among ASPs, the waking-EEGs were also within normal lim-
its, except in four cases with mild slowing of background activity without focal or
paroxysmal changes.
Minor head injuries (concussions) are, however, frequent events among ASPs.
Kaufman et al. (2001) demonstrated  a chronic sleep disturbance several years after a
minor head injury in a non-selected population. They found lower SE and more
awakenings lasting more than three minutes, but no changes in S3 or S4 as compared
with healthy controls. It therefore seems improbable that the results, which show an
increase in SWS and S4 among ASPs, were a consequence of traumatic brain injury.
5.2.  Sleep, GH-IGF-1 and leptin in anorexia nervosa
Our findings relating to the reduction in sleep duration and SWS, as well as the
increase in S1 sleep in AN are in good agreement with previously published studies
(Walsh et al., 1985; Levy et al., 1988). We observed no changes in REM parameters,
including REM latency. This most probably reflects the mild degree of depression in
the patients in the present study (Katz et al., 1984).
In most sleep studies of AN, weight gain has increased SWS (Crisp et al., 1971;
Lacey et al., 1975; Lauer and Krieg, 1992). This was also the finding in the present
study. Lacey et al. (1975) reported that, during refeeding and weight gain, SWS
initially increased, and then tended to decrease during the final stage of restoration of
weight to matched population mean levels The results of the present study revealed a
rapid normalization in SWS after only a limited weight gain, while the duration of
sleep remained shorter than in controls. It may be argued that SWS is critically
important, and the propensity for SWS is restored primarily after a period of short-
age, as evidenced, for example, by sleep deprivation and recovery sleep experiments
(Carskadon and Dement, 2000).
Higher IGF-1 levels were associated with an increase in SWS in anorectic patients. A
similar finding in elderly men has been reported previously (Printz et al., 1995). The
finding suggests that sleep quality in anorectics might be related to the status of their
GH-IGF-system. Leptin levels correlate with the amount of fat stores and changes in
energy balance as a result of fasting (Ahima et al., 2000). In animals, the depletion of
energy stores tends to favour wakefulness and activity to seek food (Danguir and
Nicolaidis, 1979). In the present study, higher leptin levels were associated with
longer and deeper sleep among both healthy controls and anorectics. In addition, low
levels of leptin correlated with “light” sleep in AN. We are not aware of any previous
reports on the relationship between leptin levels and human sleep. In the present
study, the single sample of GH collected in the morning did not reveal significant
differences between the AN and controls. This result resembles the findings of
Nussbaum et al. (1990) and Golden et al. (1994). Golden et al. (1994) postulated that
patients with AN may exhibit low GH levels at the onset of the disease. If the energy
deprivation is maintained in a chronic state of disorder, the patients may develop GH
resistance, leading to a rise in GH. The mean duration of the disorder in our patients
was only 2.2 years, suggesting that the condition was not yet chronic. This may be
the reason for our findings of low GH levels.
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IGF-1 appears to be a marker of malnutrition, and a sensitive index of nutritional
repletion in patients with eating disorders (Caregaro et al., 2001). Hill et al. (1993)
reported a stepwise increase in  IGF-1 values related to weight gain in anorectic
patients.  Our finding of an increase in IGF-1 during weight gain is in good agree-
ment with their results. The increase in serum leptin levels as a consequence of
weight gain resembles the findings of both Grinspoon et al. (1996) and Casanueva et
al. (1996). The hormones of the GH-axis, as well as leptin, have been found to
increase SWS (Steiger et al., 1992; Sinton et al., 1999), with insignificant effects on
REM sleep. The finding in AN patients that SWS was reduced while REM sleep
remained unaffected strengthens the view that the sleep disturbances in AN are linked
to changes in hormone secretion.
In conclusion, we found reduced levels of GH-axis hormone IGF-1 and leptin, as
well as reduced SWS and theta power, in patients with AN. After a limited weight
gain, the levels of IGF-1 and leptin increased, as did SWS and theta power. These
results are in agreement with previous studies of AN, and strengthen the view that
sleep problems in AN are closely associated with the physiological starvation state.
5.3.  Sleep in habitually violent offenders with antisocial personality disorder
The most striking finding in ASP males was the increase in SWS, and, in particular,
the amount of the deepest sleep stage, S4. Good agreement with the increase in SWS
from scoring data and the increase in delta (and theta) power from the spectral analy-
sis further confirm the validity of the sleep analysis.
Attention deficit hyperactivity disorder (ADHD) is a risk factor for ASP (Gittelman
et al., 1985; Mannuzza et al., 1993). Children with ADHD have been reported to
have a deficit in alertness (Lecendreux et al., 2000). They were described to be more
sleepy during the day, to have longer reaction times and to fall asleep faster than
controls. Many studies of attention deficit disorder (ADD) children have found no
changes in SWS compared with controls (Palm et al., 1992; Corkum et al., 1998;
Picchietti et al., 1999). Platon et al. (1990), however, reported a PSG study of 13
non-medicated prepubertal children with attention deficit disorder (ADD). In this
study ADD-children experienced a large number of nocturnal awakenings and a
higher SWS percentage compared with normal age-matched controls. In addition,
the two subtypes of the disorder - ADHD and ADD without hyperactivity- displayed
distinct polysomnographic correlates. Children with ADHD had a greater sleep frag-
mentation and a lesser degree of SE. In a study by Picchietti et al. (1999) the preva-
lence of periodic limb movements in sleep (PLMS) was higher in the children with
ADHD than in the control subjects. We are not aware of any PSG studies in adult
ADHD. Many of our ASP males had features of ADHD connected with conduct
disorder in their history, and it is possible to speculate that the abnormalities seen in
polysomnography can be partly explained by residual effects of childhood ADHD.
This is, however, virtually impossible to verify retrospectively.
One of the consistent alterations in normal ageing is a reduction in SWS, while REM
sleep is less affected (Bliwise, 2000). The sleep patterns of children are characterized
by large amounts of SWS (Bes et al., 1991). A quantitative change in SWS occurs
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during puberty and a reduction in SWS of almost 40% during the second decade of
life has been reported (Carskadon and Dement, 2000). As ageing proceeds, a gradual
decline in SWS is observed (Bliwise, 2000). In the present study, ASP males at the
age of 31 years had 17.2% S4, compared with the 6.3% in controls. The amount of
S4 in the 31- year-old male controls of the present study is in good agreement with
previously published studies:  5.9 % in 25-year-old men (Steiger et al., 1992) and
7.0% in 35- year- old women and men (De la Fuente et al., 2001). While the amounts
of SWS and S4 were high in the ASP, both parameters correlated negatively to age,
as in the normal population. It is possible, that the decline in SWS that normally
occurs in the course of ageing, is delayed in ASP. ASP tends to become less evident
or to remit with age (APA, 2000). Whether the change in behaviour is correlated to
changes in SWS remains to be clarified with further studies.
5.4.  Sleep research perspective of human impulsive aggression
To our knowledge, this is the first study to compare sleep in ASP with and without
BPD comorbidity.  The most striking finding was the disruption in the continuity of
sleep in persons with both personality disorders. This finding is similar to the results
reported in PSG studies of borderline persons with no ASP comorbidity (Battaglia et
al., 1993; De La Fuente et al., 2000). In ASP with and without BPD comorbidity, the
amount of S4 sleep was equally high and significantly higher than in controls. So, in
spite of many overlapping clinical features, the sleep architecture in these two per-
sonality disorders appears to differ and, in cases with comorbidity, both disorders
have their own characteristics that influence sleep. The result is in agreement with the
finding that ASP differs from that with BPD comorbidity both in research settings
and clinical outcome (Coid, 1993; Virkkunen et al., 1996; Herpertz et al., 2001).
It has been obvious for some time that aggressive behaviour in childhood is the most
stable of all early detectable personality characteristics (Loeber, 1982). The total
number of CD symptoms was reported to be the most important predictor of future
ASP (Robins, 1991). In the study by Stattin and Magnusson (1989), high ratings for
aggressiveness were characteristic of boys who subsequently committed violent
crimes and damage to public property. In our study of habitually violent offenders,
half the subjects were estimated to have severe CD and half were regarded as having
either mild or moderate CD in their history. The sleep parameters related to ASP,
SWS and especially S4, as well as theta and delta power in these sleep stages, associ-
ated strongly with the severity of previous CD. Those subjects with a large number of
CD symptoms in their childhood had a very large amount of delta sleep measured in
adulthood. This raises the interesting question of whether this exceptional deep-sleep
pattern had already developed in childhood or adolescence in these males? In a sleep
study by Coble et al. (1984), a larger number of delta waves were found in boys with
a primary diagnosis of CD compared with age-matched healthy controls, suggesting
that this deep-sleep pattern may indeed already develop in childhood or during ado-
lescence. The subjects in the Coble study were 17 pre-adolescent boys and, in fact 13
of them represented the undersocialized aggressive subtype according to DSM III,
which was regarded as the most serious form of CD. To qualify as a case of the
aggressive form, the conduct had to include robbery or violence against persons or
property, and for a case to qualify as undersocialized, there could be no more than
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one of five indicators of being “socialized”: enduring friendships, altruistic behav-
iour, feeling guilt or remorse, refraining from blaming others, and showing concern
for others (APA, 1980). It is possible to speculate that these boys in the study by
Coble et al. would be the most likely to become antisocial in adulthood.  Raine et al.
(1990) reported a retrospective waking EEG study of 101 men. It showed that adult
criminals, at the age of 24, had significantly more slow-frequency (delta and theta)
electroencephalographic activity than non-criminals at the age of 15 years. The au-
thors speculated that, in addition to social and psychological variables, measures of
both autonomic nervous system and central nervous system underarousal may facili-
tate the early prediction of subsequent antisocial behaviour and even elucidate the
etiological basis of criminality.
The notion that explosive violence may be linked to a discrete diagnosable condition
such as IED is still controversial. S4 sleep was significantly higher in men with IED
compared with those without this diagnosis. In fact, non-IED subjects did not differ
in this respect from healthy controls. The relationship between S4 and highly impul-
sive extreme aggression underlines the dimensional aspect of human aggressive be-
haviour. The result is also in agreement with previous studies suggesting that there
might be different subpopulations within ASP with a varying degree of impulsive-
ness (Linnoila et al., 1983; Coccaro et al., 1989; Virkkunen et al., 1996; Barratt et
al., 1997; Coccaro et al., 1998; Coccaro 2000). Future research is needed to clarify
whether the relationship between S4 and IED is limited to ASP or can also be found
in other populations, such as mentally-retarded patients with serious impulsive ag-
gression.
5.5.  Testosterone and sleep in persons with impulsive aggression
In the present study, there were no differences in serum testosterone levels between
antisocials with (20.4 nmol/L, SEM 1.74, age-adjusted 19.6 nmol/L, SEM 0.45) and
without BPD comorbidity (20.6 nmol/L, SEM 2.66, age-adjusted 21.9 nmol/L,
SEM 0.88). On the other hand, there was a significant difference between antisocials
with severe CD (24.1 nmol/L, SEM 1.83, age-adjusted 23.5, SEM 0.52) and those
with only mild or moderate CD (16.9 nmol/L, SEM 1.27, age-adjusted 17.4 nmol/L,
SEM 0.52). This finding is in accordance with the study by Brooks & Reddon
(1996), which reported higher single morning serum testosterone levels in 15-17-
year-old violent offenders with CD compared with boys committing non-violent or
sexual offences. The antisocials with IED (21.8 nmol/L, SEM 1.65, age-adjusted
21.3 nmol/L, SEM 0.51) displayed a tendency towards higher serum testosterone
levels than those without the diagnosis (16.4 nmol/L, SEM 2.10, age-adjusted 17.4
nmol/L, SEM 1.05). If IED is regarded as a categorical expression of recurrent
problematic impulsive and aggressive behaviour as expressed by Coccaro (2000), it
is possible to speculate that in this subgroup of antisocials, the criminal recidivism
would be emphasized. In the study by Räsänen et al. (1999), recidivists with person-
ality disorder had higher testosterone levels than non-recidivists with personality
disorder. One of the limitations of the present work is the absence of serum testoster-
one measurements in control subjects. The comparisons were limited to the different
subgroups of ASP. However, in the study by Räsänen et al (1999), the serum testo-
sterone levels of the healthy controls with approximately equal age compared with
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the controls in this study (36.4 years, SD 8.0) were mean + SD 16.8 + 4.7 nmol/L,
age-adjusted 17.5 nmol/L. In both patient groups with higher serum testosterone
levels (preceding type severe CD and IED), the percentage amount of S4 sleep and
the theta power in stages 4 and 3+4 were also significantly higher. The role of diurnal
testosterone secretion in regulating normal human sleep is still unclear. Serum testo-
sterone levels have been described as being lower when young healthy adult men
were awake than during sleep (11 pm-7 am). The levels began to rise when the
subjects fell asleep, and reached their peak value at about the time of the first REM
cycle, remaining at the same levels until awakening (Luboshitzky et al., 1999). In the
study by Leibenluft et al. (1997), leuprolide acetate was used to produce
pharmacologically- induced short-term hypogonadism in men of 18–48 years. Inter-
estingly, this procedure only caused significant reductions in the amount of S4 sleep
compared with measures taken during testosterone replacement.  This connection
between S4 sleep and testosterone, despite being associated with the testosterone-
replaced state, offers an opportunity to speculate about whether, in violent offenders
with ASP, the increased amount of S4 sleep is perhaps at least partly mediated via
elevated testosterone levels.
5.6.  The effect of a single dose of olanzapine on sleep in healthy women and
men
The structure and continuity of sleep were unaffected by olanzapine in both sexes.
Olanzapine appears to preserve the normal structure of sleep, which is of significant
benefit in the treatment of schizophrenia and increase the amount of SWS. The im-
portant finding was that the same dose of olanzapine in women induced a clear in-
crease in sleep length, while in males the increase was either absent or small, indicat-
ing that the effective dose of olanzapine on sleep may be lower in women. The body
weights or body mass indexes of men and women did not differ, suggesting that a
simple dose relationship could not explain differences in sleep parameters. The half-
life of olanzapine is longer  (36.7 vs. 32.3 h) and the clearance is lower (18.9 vs.27.3
L/h) in women than in men (Research File, Eli Lilly and Company) and this is
attributed to the differences in CYP1A2 activity between the sexes. In healthy sub-
jects, a single dose of olanzapine induces a peak plasma concentration (Tmax) in five
hours (Kassahun et al., 1997). A difference in plasma concentrations of olanzapine
between male and female patients with schizophrenia after a similar dose of
olanzapine has been reported (Kelly et al., 1999), but this difference only became
evident after five weeks of treatment. It is therefore possible, but not probable after
a single drug dose, that the sex differences seen in this study could be explained by
the longer half-life and lower clearance in women.
Olanzapine most probably affects sleep through many neurotransmitter systems. The
decrease in sleep onset is probably mediated via the blockade of histamine –H1
receptors (Reus, 1997).  In women, the REM-parameters changed significantly, and
as the relative amounts of stage 1 and 2 sleep remained unaffected, these changes
probably reflected the increase in the relative duration of SWS. This effect may also
result from the antagonistic effects of olanzapine on muscarinic cholinergic
receptors. The association between SWS and 5-HT2 receptors is well established
(Idzikovski et al., 1986; Dugovic and Wauquier, 1987). Ritanserin, a specific 5-
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HT2A/ 2C receptor antagonist doubled the absolute amount of SWS in healthy vol-
unteers (Idzikowski et al., 1986; van Laar et al., 2001). In a study by Sharpley et al.
(2000), olanzapine was reported to produce substantial and highly significant dose-
related increases in SWS in humans, probably via the blockade of brain 5-HT2C
receptors.
The 5-HT2C receptor gene has been localised to the X chromosome (Xq24) and
contains a C-G polymorphism at codon 23 (nucleotide 68) such that serine replaces
cysteine in the receptor in about 10–25 % of the different populations  (Lappalainen
et al., 1995; Lerer et al., 2001). Because of the localisation in the X chromosome,
men can be only either Ser or Cys, but women can have Ser-Ser, Ser-Cys or Cys-Cys
allelic variants. Sharpley et al. (2001) described polysomnographic findings in 24
drug-free men, twelve of whom were Ser variants and 12 Cys variants. The acute
administration of 5 mg of olanzapine had significant effects on SWS, sleep latency,
SE, wakefulness after sleep onset, stage 1 sleep and REM-sleep latency, but no sig-
nificant genotype effect or olanzapine by genotype interaction. Among women, be-
cause of different homotsygotic allelic variants, olanzapine may, however, cause
greater changes in sleep parameters. Further research into these functional 5-HT2C
gene variants is, however, needed.
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6.  CONCLUSIONS
The main results and conclusions are:
1. Reduced levels of the GH-axis hormone IGF-1 and leptin, as well as reduced
SWS and relative theta power, were found in patients with anorexia nervosa.
After limited weight gain, the levels of IGF-1 and leptin increased, as did SWS
and theta power. These results are in agreement with those in previous studies of
anorexia nervosa, and strengthen the view that sleep problems in anorexia nervosa
are closely associated with the physiological starvation state.
2. Increased deep sleep, especially S4, and increased relative delta and theta power,
were associated with habitually violent male offenders with antisocial personality
disorder. Whether this sleep architecture reflects a specific brain pathology, or a
delay in the normal development of sleep patterns in the course of ageing, needs
to be clarified with further experiments.
3. The offenders with preceding type severe conduct disorder had higher amount of
S4 sleep and higher relative theta and delta powers in this sleep stage compared
with males with only mild or moderate conduct disorder. The same kind of sleep
architecture was associated with intermittent explosive disorder.
4. Among habitually violent offenders, in the subgroups with higher serum testo-
sterone levels – preceding type severe conduct disorder and intermittent explosive
disorder – the amount of S4 sleep as well as relative theta and delta powers in this
sleep stage were increased.
5. Olanzapine appears to preserve the normal structure of sleep, which is of addi-
tional significant benefit in the treatment of schizophrenia and increase the
amount of SWS. The same dose of olanzapine in women induced a clear increase
in sleep length, while in men the increase was either absent or small, indicating
that the effective dose of olanzapine on sleep may be lower in women.
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7.  FUTURE CONSIDERATIONS
Although ASP is diagnostically always preceded by CD before the age of 15 (APA,
2000), not much is known about the physiological mechanisms that are involved in
this process. Autonomic underarousal and a low resting heart rate are reported to be
the best-replicated biological correlates of antisocial and aggressive behaviour in
child and adolescent populations. It has also been suggested that damage to the pre-
frontal cortex (PFC) can lead directly to antisocial, aggressive, and criminal behav-
iour among children (Raine, 2002). From the perspective of sleep research, the im-
portant question is whether the deep-sleep phenomenon reported in adult ASPs can
already be seen in children or adolescents with severe CD. The possible relationship
between CD and SWS needs to be clarified with future polysomnographic studies.
Prospective follow-up studies are also needed.
Neither CD nor delinquency is rare among girls. As adults, antisocial girls have been
shown to manifest increased mortality rates, substantial rates of psychiatric morbid-
ity, dysfunctional and often violent relationships, and high rates of multiple service
utilization. The rate of violent crimes among girls and women appears to be increas-
ing (Pajer, 1998; Lewis et al., 1991). One in every five female prisoners has been
reported to have ASP (Fazel and Danesh, 2002). However, it is still unclear whether
the impulsive, aggressive behaviour among women is affected by the same biological
mechanisms as among men. From the perspective of sleep research, another impor-
tant question is whether this exceptional deep-sleep phenomenon reported in men
with ASP can also be seen among antisocial women.
Many studies confirm the association between violence and schizophrenia, and an
over-representation of people with schizophrenia has been reported in offender
populations (Walsh et al., 2002). Schizophrenia patients with ASP represent a special
high-risk subgroup that is vulnerable to severe substance abuse, psychiatric impair-
ment, aggression and legal problems (Mueser et al., 1997). There are no sleep studies
of violent patients with both schizophrenia and ASP, and the interesting question is
whether the deep-sleep phenomenon can be seen among them, even though schizo-
phrenia is typically associated with reduced SWS. Clozapine, an atypical antipsy-
chotic with significant anti-aggressive effects (Fava 1997; Chengappa et al., 1999;
Chengappa et al., 2002), is widely used in institutions where habitually violent
schizophrenia patients are treated. Interestingly, in a study by Hinze-Selch et al.
(1997), clozapine significantly reduced the amounts of S4 and SWS in patients with
schizophrenia. However, also olanzapine has been reported to reduce severe aggres-
sion (Söderström et al., 2002), and opposite to clozapine, it increases SWS.
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